Abstract
The functioning of the human heart relies on complex electrical and communication systems that coordinate cardiac contractions and sustain rhythmicity. One of the key players contributing to this intricate system is the KIR2.1 potassium ion channel, which is encoded by the KCNJ2 gene. KIR2.1 channels exhibit abundant expression in both ventricular myocytes and Purkinje fibers, exerting an important role in maintaining the balance of intracellular potassium ion levels within the heart. And by stabilizing the resting membrane potential and contributing to action potential repolarization, these channels have an important role in cardiac excitability also. Either gain- or loss-of-function mutations, but also acquired impairments of their function, are implicated in the pathogenesis of diverse types of cardiac arrhythmias. In this review, we aim to elucidate the system functions of KIR2.1 channels related to cellular electrical signaling, communication, and their contributions to cardiovascular disease. Based on this knowledge, we will discuss existing and new pharmacological avenues to modulate their function.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The term “inward rectification" was first introduced in 1949 to describe a phenomenon where ion channels preferentially allow potassium current to flow into the cell rather than out of it even with an opposite driving force (Katz 1949; Nichols and Lopatin 1997). This current was described as an “inward rectifier potassium current (IK1)”. The channels which produce the current are currently known as inward-rectifier potassium (KIR) channels (Li and Dong 2010; Lopatin and Nichols 2001). Since their discovery, detailed knowledge on these channels accumulated. Expression patterns were established, rectification mechanisms deciphered, and the molecular structure is now resolved. Functional IK1 channels (KIR2.1, KIR2.2, and KIR2.3) were found by patch clamp in nearly all the cardiac myocytes (Anumonwo and Lopatin 2010). KIR2.1 is predominantly expressed in Purkinje fibers and human ventricular cardiomyocytes, KIR2.2 shows a lower degree of expression when compared with KIR2.1 in ventricles, and KIR2.3 exists relatively more in the human atria (Anumonwo and Lopatin 2010). KIR2.2 or KIR2.3 subunits can form heterotetramers with KIR2.1 to modulate IK1 (Cui et al. 2021; Panama et al. 2007, 2010; Zobel et al. 2003). Cardiac IK1 is mainly composed of KIR2.1 and KIR2.2 heterotetramers (Zobel et al. 2003). KIR2.2 subunits contributed more strongly to the single-channel conductance but with a significantly shorter opening time when compared with KIR2.1 (Panama et al. 2010). Channels that contain 2 or more KIR2.2 subunits showed similar conductance with homomeric KIR2.2 channels (Panama et al. 2010). When one KIR2.3 subunit was added to a KIR2.1 channel, the activation kinetics slowed by approximately threefold, with greater slowing when more KIR2.3 subunits were subsequently added (Panama et al. 2007). The inward rectification behavior mainly results from pore blocking by intracellular substances, such as magnesium ions (Mg2+) and polyamines (Baronas and Kurata 2014; Ishihara et al. 2009). IK1 acts in concert with many other ion channels and some forms of co-regulation at the cell biological level is present.
KIR2.1 channels play important roles in maintaining cells' resting membrane potential (RMP), regulating cell excitability, and participating in various physiological processes (Cui et al. 2021; Dhamoon and Jalife 2005; Li and Yang 2023; Reilly and Eckhardt 2021). Dysfunctional KIR2.1 channels will disrupt the hearts normal electrical activity, leading to irregular heart rhythms and potentially life-threatening arrhythmias (Crotti et al. 2020; Reilly and Eckhardt 2021; Van Der Schoor et al. 2020; Zangerl-Plessl et al. 2019). This review focuses on the importance of KIR2.1 channels in mediating cellular electrical signaling, cell communication, and their involvement in cardiovascular diseases. Now, the gained knowledge impacts our understanding of KIR2.1 pharmacology and provides new insights for their drug-design.
KIR2.1 cellular electrical signaling
Structure of the KIR2.1 channel
The first complete KIR2.1 channel sequence, encoded by the KCNJ2 gene, from the mouse, was cloned in 1993 (Kubo et al. 1993). Nearly thirty years later, the first cryo-electron microscopy derived structure of the human KIR2.1 channel was presented (Fig. 1a, b) (Fernandes et al. 2022a, b). KIR2.1 channels are formed by an interaction of four KIR2.1 proteins and contain both a transmembrane domain (TMD) and a cytoplasmic domain (CTD) (Fernandes et al. 2022b). The TMD of each protein is composed of 2 transmembrane helices M1 and M2 separated by a selectivity filter, containing the K+-channel signature sequence (T-X-G-Y/F-G). Additionally, there are two short helical components known as the slide helix and the pore helix, along with the M1 and M2 (Fig. 1b) (Fernandes et al. 2022b). The CTD is composed of the amino (NH2)- and carboxy (COOH)-terminal regions located on the cytoplasmic side forming a long inner vestibule that serves as an extension of the channel pore (Fernandes et al. 2022b; Lu et al. 1999). Around the membrane face of the CTD, an intrinsically flexible loop named “G-loop” exists which forms the narrowest portion of the ion conduction pathway (Fig. 1b) (Fernandes et al. 2022b; Hibino et al. 2010). Along the TMD and CTD, there are many channel activator and inhibitor binding sites that interfere with the open and closed state of the channel and serve the function of KIR2.1 as an inward rectification potassium channel (Hibino et al. 2010). Some of these sites might serve as targets in drug development.
Physiological functions of KIR2.1 channels and the cardiac action potential
KIR2.1 channels play a vital role in mediating cellular electrical signaling in various tissues, including the cardiovascular system (De Boer et al. 2010a). In resting cardiomyocytes, the potassium equilibrium potential, Ek, is slightly more negative than the resting membrane potential. Therefore, at the level of resting membrane potential, KIR2.1 channels exhibit a certain outward current. This outward current can clamp the membrane potential at a more negative level, which helps to stabilize the resting membrane potential and regulate excitability. This outward current tends to zero after further depolarization because of the inward rectification (Hibino et al. 2010). The lack of outward conductance of IK1 at positive potentials permits maintenance of a positive membrane potential established by several depolarizing currents (Hibino et al. 2010; Kubo et al. 1993; Lopatin and Nichols 2001). Then time dependent closure of depolarizing channels and concomitant opening of voltage-gated potassium channels allows a rapid efflux of K+ ions, leading to a repolarization (Grider et al. 2023). KIR2.1 channels play a role in the terminal phase of the cardiac action potential (AP) (Reilly and Eckhardt 2021). When the membrane potential starts to become more negative again, the KIR2.1 channels gradually recover their conductance (Hibino et al. 2010). This recovery allows a relatively large outward flow of potassium ions to pass through KIR2.1 channels which contributes to shortening of the cells’ action potential duration (APD) (Hibino et al. 2010). During these phases in the repolarization process, the IK1 inward current component will prevent a repolarization overshoot. Hence, the IK1 current contributes to the normal duration of the AP and stability of the resting membrane potential (Fig. 2). The IK1 activity helps to maintain the heart's normal electrical activity and reduces the likelihood of arrhythmias. Loss- or gain-of-function mutations or acquired dysregulation of the channel lead to various pathological conditions, these mutations may impair the channel's ability to properly open or close, resulting in modified ion conductance and disrupted cellular excitability.
Opening and closing mechanisms of KIR2.1 channels
KIR2.1 channels exhibit unique opening and closing mechanisms that regulate their activity and play a crucial role in cellular physiology. The channel opening and closing mechanisms of KIR2.1 channels involve various factors, including membrane voltage, intracellular polyamines, lipids, modulatory proteins, several cations, and others (Hibino et al. 2010).
At membrane potentials negative to the reversal potential (Ek), the channels exhibit a high open probability, facilitating the influx of potassium ions (Anumonwo and Lopatin 2010; Dhamoon and Jalife 2005; Li and Dong 2010). Conversely, the channels undergo pore block at membrane potentials positive to the voltage threshold, resulting in closure and diminished ion conductance (Anumonwo and Lopatin 2010; Dhamoon and Jalife 2005; Li and Dong 2010). The driving force behind ion movement is determined by a combination of an electrical and potassium gradient over the plasma membrane (Gadsby 2009). Changes in membrane potential due to depolarization or hyperpolarization led to alterations in the electric driving force (membrane potential Vm—reversal potential Ek), the altered electric driving force works on the chemical driving force, subsequently influencing K+ ion movement in or out of the cell. Therefore, it can be explained that even though KIR2.1 channels are not voltage-gated by itself, they can still be influenced by the membrane potential.
KIR2.1 channels exhibit a constant permeability when the inward or slightly outward potassium driving force is present. However, when the driving force becomes significantly outward, K+ permeability declines rapidly. The mechanism underlying this driving force-induced permeability change primarily involves the blockage of outward potassium current by intracellular Mg2+ or polyamines such as spermine and spermidine (Ficker et al. 1994; Ishihara et al. 2009; Nichols and Lee 2018). These positively charged substances bind to negatively charged amino acids within the pore of the KIR2.1 channel, thereby reducing the conductance of outward currents (Fujiwara and Kubo 2006). Early studies showed that Mg2+ dependent IK1 block is the cause of inward rectification, but increasing amount of studies now proved that spermine is the main factor responsible for inward rectification, followed by spermidine, putrescine and then Mg2+ (Anumonwo and Lopatin 2010; Ficker et al. 1994; Kubo 1996; Lopatin et al. 1994; Nichols and Lee 2018). This KIR2.1 channel block occurs in a two-step process. The initial step, which is weakly voltage-dependent, involves the entry and interaction of polyamines into the KIR2.1 channel pore (Anumonwo and Lopatin 2010; Nichols and Lee 2018). This interaction occurs at a specific site of negatively charged amino acids (E224 and E299) located in the C-terminus of the channel (Fig. 1c) (Anumonwo and Lopatin 2010; Kubo and Murata 2001; Nichols and Lee 2018). The subsequent step, which is more strongly voltage-dependent, involves the movement of polyamines to a deeper binding site, in the TMD, at the D172 residue (Fig. 1c) (Anumonwo and Lopatin 2010; Kubo and Murata 2001). During membrane hyperpolarization, the time-dependent activation of strong inward rectifiers reflects the exit of polyamines from the pore (Ishihara et al. 1996; Ishihara and Ehara 2004).
KIR2.1 channels engage in interactions with diverse regulatory proteins, including protein kinase A (PKA), protein kinase C (PKC), and Phosphatidylinositol-4,5-bisphosphate (PIP2) (D'avanzo et al. 2010; Karschin 1999; Reilly and Eckhardt 2021; Trum et al. 2020; Xie et al. 2008). For example, an earlier study showed that the open probability of a recombinant KIR2.1 and KIR2.3 is inhibited by both PKA and PKC mediated phosphorylation (Karschin 1999). PIP2, a crucial lipid constituent of the plasma membrane, acts as a positive modulator of KIR2.1 channels by binding to specific sites within the channel structure, thereby regulating the channel and enhancing its open probability (D'avanzo et al. 2010; Fernandes et al. 2022b; Li et al. 2015; Ruddiman et al. 2023; Xie et al. 2008).
Regulation of IK1 by different cations
Three physiological relevant cations, i.e. K+, Na+, Ca2+, and the poisonous Ba2+ are well known to affect the KIR2.1 channel function (Anumonwo and Lopatin 2010; Bhoelan et al. 2014; Hibino et al. 2010). Elevating the concentration of extracellular K+ ([K+]o) tends to enhance IK1 (Chang et al. 2010; Ishihara 2018; Kubo 1996; Liu et al. 2011). For the inward component, this is easy to explain since a higher [K+]o increases the chemical driving force for K+ flow into the cells. But with regard to the outward component, several hypotheses have been raised. Some researchers think that the elevated [K+]o activates the channel, allowing more K+ flow out of cells, thus interfering with the channel’s open probability (Pennefather et al. 1992). Some prefer the view that elevated [K+]o weakens the polyamine or Mg2+-induced rectification of the channel so that the peak IK1 current is increased (Kubo 1996). Some overturned these two hypotheses, and they proved that the open probabilities of the channel and spermine-binding kinetics were not interfered when the [K+]o increases at a constant driving force, but the conductance of the channel was increased (Liu et al. 2011). In addition, some researchers proved that the [K+]o increase in IK1 is not caused by activating the channel but is caused by physiologically relevant competition from impermeant extracellular Na+ or Ga2+ (Chang et al. 2010; Ishihara 2018). Increased concentrations of extracellular Na+ ([Na+]o) reduce the outward IK1 due to pore blocking and surface charge effect (Chang et al. 2010; Ishihara 2018).
Many studies agree that IK1 is Ca2+-sensitive, but the modulatory effects of Ca2+ on IK1 are controversial (Nagy et al. 2011, 2013; Wagner et al. 2009). In some cases, IK1 was shown to decrease with elevated intracellular or extracellular Ca2+ ([Ca2+]i/o) (Chang et al. 2010; Fauconnier et al. 2005; Matsuda and Cruz Jdos 1993; Mazzanti and Defelice 1990; Zaza et al. 1998). In ventricular myocytes isolated from failing rat hearts, IK1 was observed to decrease because of the blocking effect by elevated [Ca2+]i (Fauconnier et al. 2005). Similar to [Na+]o, the increased [Ca2+]o was reported to reduce IK1 by blocking the channel pore and the effect of altered surface charge (Chang et al. 2010). Calcium/Calmodulin-dependent protein kinase II (CaMKII), an enzyme that relies on elevated [Ca2+]i for its activation, regulates IK1 (Ma et al. 2021; Nagy et al. 2013; Wagner et al. 2009). Chronic activation of CaMKII was reported to downregulate KIR2.1 mRNA expression and decrease IK1 in a mouse model (Wagner et al. 2009). In addition, IK1 also shows an increase with rising [Ca2+]i in some other cases (Nagy et al. 2011, 2013). For example, Ca2+ influx during exercise was shown to increase IK1 (Nagy et al. 2011). Another study showed that elevated [Ca2+]i results in an increase in IK1 in isolated dog ventricular cardiomyocytes, and IK1 was significantly reduced by inhibiting CaMKII (Nagy et al. 2013). This [Ca2+]i-dependent augmentation of IK1 shortened the repolarization phase of the AP, suggesting that it could serve as a protective mechanism against cardiac arrhythmias induced by the calcium overload (Nagy et al. 2013). Therefore, the influence of Ca2+ on IK1 appears to be dependent on the specific experimental conditions and cellular context, leading to conflicting findings among studies.
Ba2+ is an effective KIR2.1 channel blocker leading to a decrease in the IK1 current, and this block is both voltage and time-dependent (Imoto et al. 1987). Blockage is achieved by a Ba2+ ion entering and blocking the pore at the selectivity filter. At more negative membrane potentials, Ba2+ has a strong sensitivity to the channel and causes stronger and more rapid block than when the membrane potential becomes more positive (Imoto et al. 1987). Cs+ and Sr2+ also exhibit full inhibitory activity immediately at the beginning of each application period, but these 2 blockers were shown less potent than Ba2+ (Sanson et al. 2019). A recent study revealed an additional mechanism of blocking apart from pore obstruction of external Ba2+ and Cs+ (Gilles 2022). The work suggests interaction of the ions to an extracellular side of the channel. Furthermore, blockage is independent of the K+ ion flux (Gilles 2022).
KIR2.1 channels in their cellular context
Channel trafficking
Channel trafficking refers to the process by which channel proteins are transported to their appropriate cellular destinations within a cell or between different cellular compartments (Steele et al. 2007). In general, ion channel trafficking can be divided into forward trafficking (towards the plasma membrane), backward trafficking (removed from the plasma membrane), and recycling that couples backward to forward trafficking mechanisms (De Git et al. 2013; Hager et al. 2021) (Fig. 3). It is an essential cellular mechanism that ensures proteins are delivered to the correct location for their proper function. Proteins are synthesized in the endoplasmic reticulum (ER), and only properly folded and assembled channels are exported from the ER to the Golgi apparatus (Steele et al. 2007). The field of cystic fibrosis, in which mutations in the affected chloride channels result often in aberrant channel expression at the plasma membrane, demonstrated the clinical efficacy and specificity of pharmacological chaperones to restore normal channel function (Gramegna et al. 2021).
The KIR2.1 protein has an ER export sequence in the C-terminus (374FCYENEV380, numbers based on human sequence) and a Golgi export sequence in the N-terminus (44RSRFVK49) which play a role along the intracellular forward trafficking route (Hofherr et al. 2005; Ma et al. 2001, 2011; Stockklausner et al. 2001; Stockklausner and Klocker 2003). Disruption of the 374FCYENEV380 motif (GFPKIR2.1-E377/379A) resulted in an accumulation of KIR2.1 channel proteins in the ER and led to a decrease in its presence in both the Golgi and the plasma membrane (Ma et al. 2001; Stockklausner and Klocker 2003). The S369X mutant led to a premature stop codon at S369, causing a loss of 59 amino acids in the C-terminal (Doi et al. 2011). Individuals carrying the S369X mutation will lose the ER export motif and be diagnosed with Andersen-Tawil syndrome (ATS) (Doi et al. 2011). Disruption of the 44RSRFVK49 motif leads to an accumulation of KIR2.1 channel proteins within the Golgi and causes a significant reduction of properly folded KIR2.1 anchoring on the cell membrane (Hofherr et al. 2005; Ma et al. 2011; Stockklausner and Klocker 2003). This Golgi export sequence can form a recognition site for the clathrin adaptor proteins (AP-1), thereby marking KIR2.1 channel proteins for packaging into different clathrin-coated vesicle (Hofherr et al. 2005; Ma et al. 2011). Besides the N-terminal sequence, a C-terminal ATS mutation (KIR2.1△314–315) blocks Golgi exit similarly (Ma et al. 2011). The colocalization of this mutant channel with trans- and cis-Golgi markers suggests that the mutation blocks channel protein trafficking out of the Golgi (Ma et al. 2011).
Disruptions in protein trafficking can have severe consequences for cellular function and can lead to various diseases. Loss-of-function mutation associated and acquired disruptions in normal KIR2.1 protein trafficking can result in altered membrane expression of KIR2.1 channels resulting in, for example, abnormal repolarization (De Git et al. 2013; Hager et al. 2021). This can contribute to the development of ATS and an increased risk of arrhythmias (Hibino et al. 2010). Proper KIR2.1 channel trafficking is also important in other systems besides the cardiovascular system (Akyuz et al. 2022; Binda et al. 2018). For example, decreased expression of KIR2.1 channels in neurons can result in altered membrane potentials and increased neuronal excitability, these changes can contribute to the development of epilepsy (Akyuz et al. 2022). In contrast, enhanced expression of KIR2.1 channels was involved in the autism spectrum disorder (ASD) (Binda et al. 2018).
KIR2.1 channel trafficking can be regulated by various signals and factors. Interactions with other proteins can lead to altered trafficking or degradation of the channel. The hypomorphic KIR2.1Δ314–315 mutation of the KIR2.1 channel disrupts Golgi trafficking by deficient AP-1 binding, leading to the development of ATS (Ma et al. 2011). In the Golgi apparatus, Golgin-97 which belongs to membrane and cytoskeleton tethers helps capture the KIR2.1-containing vesicles to Golgi and facilitates KIR2.1 transport into AP-1 associated vesicles (Hager et al. 2021; Taneja et al. 2018). Even though Golgin-97 is necessary for the forward trafficking of the KIR2.1 channel proteins, it also mediates the retrograde transport of endosomes to the Golgi (Shin et al. 2017). The γ-aminobutyric acid type A receptor interacting factor-1 (GRIF-1) plays a role in the forward trafficking by binding with the C-terminus of KIR2.1, then promoting the trafficking of vesicles and facilitating the anchoring of KIR2.1 channel protein on the cell membrane (Grishin et al. 2006; Hager et al. 2021). SAP-97 which is a membrane-associated scaffolding protein, regulates the NaV1.5/KIR2.1 complex, leading to a decrease in the internalization of KIR2.1 (Milstein et al. 2012). Ras-related C3 botulinum toxin substrate 1 (Rac1) showed strong specificity with KIR2.1 channels, as KIR2.2 and KIR2.3 channels were not involved in the regulation by Rac1 (Boyer et al. 2009). Data suggested that inhibiting Rac1 resulted in approximately a twofold increase in KIR2.1 channel expression by interfering with endocytosis, likely via a dynamin-dependent pathway (Boyer et al. 2009). The endosomal sorting complex required for transport (ESCRT) was required for the lysosome-dependent degradation of KIR2.1 in human cells and regulates the level of KIR2.1 at the cell membrane (Hager et al. 2021; Kolb et al. 2014). Clathrin-mediated endocytosis and late endosomal or lysosomal activities are also critical for the degradation of KIR2.1 channels (Jansen et al. 2008; Li et al. 2023; Varkevisser et al. 2013). Our previous study proved that propafenone causes intracellular accumulations of KIR2.1 most likely by inhibiting the function of the late endosome (Li et al. 2023). Intracellular signaling pathways impact the trafficking of KIR2.1 channels, for example, the Ras-MAPK pathway modulates the IK1 current by altering the channel density on the cell membrane (Giovannardi et al. 2002). In addition, functional actin and tubulin cytoskeleton systems are crucial for the forward trafficking of KIR2.1 channels, and in turn functional membrane expression and anchoring of the KIR2.1 channel also regulate the actin filament dynamics (Li et al. 2022; Wu et al. 2020). The initial backward trafficking depends on a functional dynamin system (Li et al. 2022).
Coregulation of functional pairs
From a physiological viewpoint different ion channels have to coordinate their activity, for example to generate proper action potential characteristics. To this end, several ion channels are found to make functional pairs, also referred to as channelosomes (Gutierrez et al. 2024). Sodium inward current (INa) and IK1 current are two important ionic currents that control the ventricular excitability (Varghese 2016). Strong evidence showed the existence of reciprocal modulations between NaV1.5 and KIR2.1 channels (Dago et al. 2022; Goversen et al. 2016; Li et al. 2021b; Macías et al. 2022; Matamoros et al. 2016; Milstein et al. 2012; Perez-Hernandez et al. 2018; Ponce-Balbuena et al. 2018; Utrilla et al. 2017; Varghese 2016). KIR2.1 and NaV1.5 channels physically interact and form the macromolecular complexes (KIR2.1- NaV1.5 channelosomes) during transportation from sarcoplasmic reticulum (SR) to Golgi, and then trafficking together to the cell membrane (Gutierrez et al. 2024; Ponce-Balbuena et al. 2018). NaV1.5 channel proteins can reduce the internalization of KIR2.1 channel proteins to promote the channel presence at the cell membrane (Milstein et al. 2012). Trafficking defects in the NaV1.5 channel will cause a decreasing IK1 in addition to INa (Perez-Hernandez et al. 2018; Reilly and Eckhardt 2021). Similarly, trafficking defects of KIR2.1 lead to a down-regulation of NaV1.5 expression and current density (Macías et al. 2022). Increased expression of NaV1.5 channels concurrently induces the upregulation of the KIR2.1 channel expression (Milstein et al. 2012). In a human in vitro cardiomyocyte myocardial infarction model, a decreased NaV1.5 and KIR2.1 protein expression accompanied by reductions in INa and IK1 was observed, and functional expression of both channels could be restored by liver-derived fibroblast growth factor 21 (Li et al. 2021b). The reciprocal modulation between KIR2.1 and NaV1.5 relies on a specific C-terminal PDZ-binding domain located in KIR2.1 and a PDZ-like binding domain located at the N-terminus of the NaV1.5 channel (Matamoros et al. 2016). Dysfunction of NaV1.5 and KIR2.1 channelosomes is associated with severe cardiac diseases, such as ATS, Short QT syndrome type 3 (SQT3), Brugada syndrome and Duchenne muscular dystrophy (Gutierrez et al. 2024). However, the effect of KIR2.1 channel expression on NaV1.5 channels remains controversial and might be stimulus specific. For example, our previous study demonstrated that propafenone enhances the expression level of KIR2.1 channel proteins without interfering with NaV1.5 channel expression (Li et al. 2023; Milstein et al. 2012). Another study that is inconsistent with the reciprocity modulation demonstrates that in synapse-associated protein-97 (SAP-97) knockout mouse cardiomyocytes, IK1 was decreased but INa was not altered (Gillet et al. 2015).
Gap junctions are specialized structures that allow direct communication and electrical coupling between cells, which is critical for synchronized activity in tissues like the heart (Gao et al. 2015). Gap junctions facilitate the conduction of APs from one myocyte to another (Veeraraghavan et al. 2014). Functional gap junctions exist of connexin proteins (Zhang et al. 2018). The major gap junction connexin between ventricular cardiomyocytes is Connexin-43 (Cx-43) (Gao et al. 2015). Some studies demonstrated that the expression levels of Cx-43 and KIR2.1 channel proteins altered synchronously after treatment (Lee et al. 2015; Qian et al. 2021; Raad et al. 2021; Zhang et al. 2018, 2013b). For example, the expression levels decreased in model rat myocardial tissues and were elevated after pretreatment with pinocembrin (Zhang et al. 2018). The relationship between Cx-43 and KIR2.1 channels probably lies in their contribution to the overall electrical behavior of cardiac tissues. A study transfected the gene of KIR2.1 channel (KCNJ2), NaV1.5 channel (SCN5A), and the Cx-43(GJA1) in HEK-293 T cells proved that overexpression of Cx-43 in these transfected cells shows enhanced intercellular coupling and permits rapid AP propagation (Kirkton and Bursac 2011). Another study transfected varying ratios of KIR2.1 and bacterial sodium channel (NaVD) with and without Cx-43 in cells, found more Ca2+ responses were generated in cells expressed with Cx-43 (Thomas and Hughes 2020). Cx-43 is a Ca2+-dependent channel, and IK1 is also Ca2+-sensitive (Lurtz and Louis 2007; Nagy et al. 2011). In this perspective, perhaps Ca2+ is the bridge between KIR2.1 and Cx-43. However, in some cases of human AF, the KIR2.1 channel expression and IK1 current were increased without interfering with the localization and expression of the Cx-43 (Girmatsion et al. 2009). These different alterations may suggest an overlapping regulatory pathway between the channel of KIR2.1 and Cx-43.
KIR2.1 related cardiovascular diseases and pharmacological avenues
KIR2.1 channel activity directly affects the cardiac electrical stability of the human heart (Hibino et al. 2010; Li and Dong 2010; Reilly and Eckhardt 2021). The gain-of-function and loss-of-function of the KIR2.1 channel can both cause different kinds of arrhythmias (Hibino et al. 2010). Some of the mutations on the KCNJ2 gene associated with cardiovascular diseases are shown in Fig. 4. Besides genetic causes, impaired KIR2.1 channel function resulting from drugs, electrolyte abnormalities, etc. can also lead to the development of some acquired diseases (Kim 2014; Maruyama et al. 2011). The following KIR2.1 channel diseases are associated with the heart.
The Anderson-Tawil syndrome
The Anderson-Tawil syndrome (ATS), characterized by periodic paralysis, cardiac arrhythmias, and dysmorphic features, is caused by loss-of-function mutations in the KCNJ2 gene (Jongsma and Wilders 2001; Perez-Riera et al. 2021). ATS is classified as Long QT Syndrome 7 (LQT7) (Tristani-Firouzi et al. 2002). Because it impedes myocellular repolarization, as individuals display an extended QT interval on their electrocardiograms (ECGs) (Tristani-Firouzi et al. 2002). But unlike other types of LQTS, it causes distinct ventricular arrhythmias with a lower susceptibility to sudden cardiac death, and it also interferes with other systems in addition to the heart's electrical system (Tristani-Firouzi et al. 2002). However, subsequent clinical findings conclude that the Q-U interval is markedly prolonged instead of the QT interval, so some researchers prefer to name this disease ATS type 1 (AST1) rather than LQT7 (Adler et al. 2020; Delannoy et al. 2013; Moreno-Manuel et al. 2023; Nguyen et al. 2013; Zhang et al. 2005b). An LQTS-specific genetic study from 2020 shows that the evidence to classify ATS as LQTS is limited (Adler et al. 2020). ATS1 is a rare autosomal dominant inherited disorder that accounts for 60% of the ATS incidence (Veerapandiyan et al. 2018). ATS2 which is caused by the mutation of KCNJ5, coding for a G protein-activated inward-rectifier channel, accounts for 15%, the remaining ATS cases are not yet linked to a genetic variant (Kokunai et al. 2014; Perez-Riera et al. 2021).
ATS shares some phenotypes with the catecholaminergic polymorphic ventricular tachycardia (CPVT) (Le Tanno et al. 2021; Nguyen and Ferns 2018). Mutations (G144D, T305S, R67Q, V227F, R82W) in the KCNJ2 gene were identified in individuals who had the clinical phenotype features of CPVT (Kalscheur et al. 2014; Kimura et al. 2012; Tester et al. 2006). However, a gene curation expert panel (GCEP) deemed that KCNJ2 gene mutations scored with limited evidence as single gene causes for CPVT and classified the KCNJ2 gene as “disputed” (Walsh et al. 2022). The GCEP prefers that these KCNJ2 mutations were more accurately corresponded to a cardiac-restricted expression of ATS (Walsh et al. 2022).
There are no standardized treatment methods or guidelines for ATS (Moreno-Manuel et al. 2023). Medication management such as beta-blockers or anti-arrhythmic drugs may be prescribed to help control abnormal heart rhythms and calcium channel blockers may be used to manage the potassium imbalances that can occur in ATS1 (Kostera-Pruszczyk et al. 2015; Perez-Riera et al. 2021; Sansone and Tawil 2007). For specific symptoms, like periodic paralysis caused by low serum potassium levels, daily potassium supplementation will be beneficial (Statland et al. 2018). The elevated serum potassium level also benefits patients who suffer a long QT interval at the same time (Sansone and Tawil 2007). Because of the rarity of ATS (1: 500,000–2,000,000), it is very difficult to collect sufficient patients for clinical trials (Barron-Diaz et al. 2020). Therefore, animal models or cell models of ATS are highly desirable. Even though various treatments have been reported in the medical literature, they seldom target KIR2.1 channels. Class 1c antiarrhythmic drugs like flecainide and propafenone together with beta-blockers are used to treat ATS1 (Barajas-Martinez et al. 2011; Delannoy et al. 2013). Interestingly, flecainide and propafenone have direct drug-channel interactions with the KIR2.1 channel by binding with Cysteine 311 (Cys311), thereby increasing IK1 current by reducing the binding affinity of polyamine (Caballero et al. 2010; Gomez et al. 2014). However, the efficacy of these two drugs was controversial in the clinical setting (Barajas-Martinez et al. 2011; Bienias et al. 2018; Junker et al. 2002; Nguyen and Ferns 2018). Researchers have been exploring various compounds and approaches that modulate the activity of KIR2.1 channels, aiming to find out some potential therapeutic methods. Zacopride was originally used as an antiemetic agent, but its effects on the cardiovascular system were getting noticed (Smith et al. 1989). Zacopride acts as a KIR2.1 channel opener leading to hyperpolarization, shortening the APD, and suppressing aconitine, acute ischemic and reperfusion-induced arrhythmias in rat (Liu et al. 2021, 2012; Zhai et al. 2017). Unfortunately, the Zacopride work is still hampered by a case of scientific misconduct (Korte and Van Der Heyden 2017). The small-molecule drug BGP-15 was reported to stabilize the IK1 current amplitude after cells suffered PIP2 depletion (Handklo-Jamal et al. 2020a). BGP-15 probably can regulate the level, availability, or localization of PIP2, thereby stabilizing the open state of the KIR2.1 channel (Handklo-Jamal et al. 2020a). Tetramisole was shown to increase the IK1 current by facilitating the forward trafficking of the KIR2.1 channel, deactivation PKA signaling, and restoring the Ca2+ balance (Liu et al. 2022). A desmosome protein Plakophilin 4 (PKP4) was reported as an IK1 up regulator by BioID and patch clamp analysis (Park et al. 2020). These potential KIR2.1 positive modulators of IK1 (AgoKirs (Van Der Schoor et al. 2020)) are interesting candidates and starting points in generating pharmacotherapy to relieve or resolve symptoms of ATS (Table 1).
Short QT syndrome type 3
Short QT syndrome (SQTS) is a rare genetic disorder characterized by an abnormally short QT interval on the ECG, indicating a shortening of the depolarization-repolarization cycle for each heartbeat (Dewi and Dharmadjati 2020). The shortened QT interval can disrupt the heart's normal electrical activity, potentially leading to cardiac events, and increasing the risk of life-threatening arrhythmias, such as ventricular fibrillation and sudden cardiac arrest (Dewi and Dharmadjati 2020; Hancox et al. 2023; Kim et al. 2021). Schwartz's score helps in diagnosing SQTS and its subtypes (Dewi and Dharmadjati 2020). There are now 6 subtypes of SQTS recognized, including SQTS3, which is associated with a gain-of-function mutation in the KCNJ2 gene (Dewi and Dharmadjati 2020). The first reported mutation site is at amino acid 172, mutated from aspartic acid to asparagine (D172N) (Priori et al. 2005). D172 is an important binding site for polyamines, therefore the D172N substitution in the KCNJ2 gene (gain-of-function mutation) can lead to abnormal functioning of KIR2.1 channels, increasing the outward current and subsequently inducing a shortened QT interval (Anumonwo and Lopatin 2010; Du et al. 2021; Priori et al. 2005). The KCNJ2 gain-of-function mutations M301K and E299V were found in an 8-year-old girl and an 11-year-old boy, respectively (Deo et al. 2013; Hattori et al. 2012). Both showed extremely short QT intervals together with paroxysmal atrial fibrillation (AF) (Deo et al. 2013; Hattori et al. 2012). Another SQTS3-related gain-of-function mutation K346T was reported in 2014 (Ambrosini et al. 2014). F58S was reported as a gain-of-function mutation of KIR2.1 in 2018, the increased IK1 decreased the neuro excitability and shorted the heart QT interval at a borderline level so that the patient was only diagnosed as an autism spectrum disorder (ASD) (Binda et al. 2018).
The first SQTS was reported in 2000 and SQT3 was first described in 2005. Since, specific treatment of SQTS is still poorly defined (Gussak et al. 2000; Priori et al. 2005; Rudic et al. 2014). The implantable cardioverter defibrillator (ICD) is used as the first-line therapy in SQTS but with an increased risk of inappropriate shock (Dewi and Dharmadjati 2020). The Class Ia antiarrhythmic drug quinidine is regarded as the most effective pharmacological therapy in SQTS patients (Dewi and Dharmadjati 2020; Hancox et al. 2023; Rudic et al. 2014). Quinidine can prolong the APD of the ventricular cells, increase the effective refractory period (ERP), and reduce the susceptibility of ventricular tissues associated with SQT3 (Luo et al. 2017a). In addition, chloroquine (CQ) prolongs the APD by reducing IK1, and probably other repolarizing currents (IKr, Ito), which may be a potential agent for SQT3 treatment in the future (Luo et al. 2017b; Szendrey et al. 2021; Wagner et al. 2010). On a longer time-scale, CQ application results in lysosomal accumulation of KIR2.1 proteins (Jansen et al. 2008). More specific IK1 inhibiting drugs (AntaKirs) may find a place in SQT3 pharmacotherapy.
Familial atrial fibrillation
AF is characterized by an irregular and often accelerated heart rhythm with a high risk of stroke, heart failure, and various other complications related to the heart and currently affects over 33 million individuals worldwide (Al-Khatib 2023; Wijesurendra and Casadei 2019). Several known risk factors are high blood pressure, sleep disorders, diabetes, obesity, chronic lung diseases, coronary artery disease, congenital defects, etc. (Benjamin et al. 2021; Buch et al. 2003; Christophersen and Ellinor 2016; Chugh et al. 2014; Lau et al. 2017). Between 5 and 15% of patients with AF have a familial predisposition, and there are many mutations related to Familial Atrial Fibrillation (FAF) (Christophersen and Ellinor 2016; Darbar et al. 2003). Xia et al. first analyzed the distribution of the KCNJ2 gene in relatives of Chinese patients with FAF in 2005 (Xia et al. 2005). The mutation V93I was found in all 30 unrelated kindreds, whereas none was abnormal in 420 unrelated healthy Chinese individuals (Xia et al. 2005). Electrophysiologic studies also confirmed the increase of the outward currents generated by V93I-KIR2.1 channels The enhanced activity of KIR2.1 channels resulted in a shorter APD, leading to the development of AF. However, in a recent study, one V93I carrier shows an evident QT prolongation, which indicates that its clinical appearance is not so consistent (Zaklyazminskaya et al. 2022).
The treatment and prevention of AF was summarized by Al-Khatib (Al-Khatib 2023). Ongoing studies have explored gene therapy approaches aimed at restoring normal KIR2.1 channel functions. MicroRNA-26 (miR-26) was downregulated in KCNJ2-upregulated AF animals and patients, and the knockdown, inhibition, or binding-site mutation of miR-26 enhanced the expression of KCNJ2, establishing that KCNJ2 is a miR-26 target (Luo et al. 2013). Long noncoding RNA TCONS-00106987 (lncRNA TCONS-00106987) was reported to increase the expression of the KIR2.1 channel proteins in rabbit models by endogenously competing with miR-26, suggesting that the mutual regulation between lncRNA and miRNA can be a potential therapeutic target for AF (Du et al. 2020). The pentamidine analogue PA-6 (Table 1) was presented as a specific IK1 inhibiting compound able to terminate AF in a goat model of recently induced AF, but not in patient dogs with long-lasting AF (Ji et al. 2017a, b; Szatmari et al. 2018).
Acquired diseases associated with disturbed KIR2.1 channel functioning
Besides genetic diseases, altered KIR2.1 channel function or expression levels can also contribute to, or at least associate with, the development of some acquired diseases. Upregulation of IK1 was found to be involved in chronic atrial fibrillation (Dobrev et al. 2002; Zhang et al. 2005a). Many studies (clinical, animal, and computer simulation) have demonstrated that the weakening of IK1 which contributes to AP prolongation, is an important mechanism contributing to the development of arrhythmias in heart failure (Akar et al. 2005; Husti et al. 2021; Jian et al. 2022; Kaab et al. 1996; Li et al. 2004). Decreased IK1 was also associated with myocardial infarction, hypotrophy, and reperfusion arrhythmias (Aimond et al. 1999; Li et al. 2019; Liu et al. 2021; Roman-Campos et al. 2009). Correction of KIR2.1 channel function by pharmacologic or other molecular means will be beneficial in alleviating these diseases. However, the safety of the IK1 modulators should never be eliminated. First, since in the heart lengthening or shortening the APD duration may lead to life-threatening arrhythmias. Secondly, KIR2.1 channels have many functions in other organ systems and tissues which should not be compromised by efforts to normalize KIR2.1 function in the heart. This latter safety issue is likely a bigger problem in acquired than in genetically originated diseases.
Future development of KIR2.1 pharmacology
With advancements in understanding the role of the KIR2.1 channel in various diseases, there may be an increased focus on developing targeted therapies that modulate the activity of the channel. This could involve the design of KIR specific drugs and targeted gene therapy. The KIR drugs should target KIR2.1 channels to enhance (AgoKir) or inhibit KIR2.1 (AntaKir) function without further interactions, depending on the therapeutic goal.
Drugs targeting PIP2
PIP2 acts as a signaling molecule and as indicated above is involved in the modulation of the KIR2.1 channels, i.e. the presence of PIP2 in the cell membrane is necessary for stabilizing the open state of KIR2.1 channels (D'avanzo et al. 2010; Xie et al. 2008). When the affinity between PIP2 and KIR2.1 channels is reduced, KIR2.1 channels tend to lose function, leading to changes in membrane potential and cellular excitability (Donaldson et al. 2003; Xie et al. 2008). PIP2 binding affinity also determines the sensitivity of other KIR2.1 modulators like pH, PKC, and Mg2+ (Du et al. 2004; Gada and Logothetis 2022). Many studies have shown that the mutation defects affecting PIP2 binding constitute a major pathogenic mechanism of ATS (Choi et al. 2007; Cruz et al. 2023; De Los Monteros et al. 2022; Donaldson et al. 2003; Handklo-Jamal et al. 2020a, b; Lopes et al. 2002; Tan et al. 2013). Developing drugs that enhance PIP2-KIR2.1 channel interaction and thereby activate IK1 to alleviate ATS will be promising. In this direction, the small molecular BGP-15 (Table 1) showed increased PIP2 sensitivity in ATS variants (Handklo-Jamal et al. 2020a). A recent computer simulation study showed that the severity of the ATS mutation directly correlates with the electrostatic forces of the transmembrane PIP2 binding region (De Los Monteros et al. 2022). This may point to a way to relieve arrhythmias by neutralizing the positive charge in the KIR2.1 channel pore. By contrast, excessive KIR2.1 channel activity can also be corrected by blocking PIP2 mediated activation of the channel (Lopez-Izquierdo et al. 2011b; Ponce-Balbuena et al. 2009; Ruddiman et al. 2023). Drugs targeting PIP2, and more specifically the PIP2 dependent KIR2.1 activity, will be an interesting pharmacotherapeutic option for patients who suffer from diseases caused by abnormal KIR2.1 activities like ATS.
Drugs interfering with channel trafficking
Disruptions and enhancement in channel trafficking can lead to alterations in KIR2.1 ion channel expression on the cell surface, which can lead to diseases like ATS, and SQT3 (Ambrosini et al. 2014; Bendahhou et al. 2003). In the context of drug development, targeting channel trafficking represents a potential strategy to modulate ion channel activity to treat certain channelopathies or other related disorders. There are various ways that drugs can interfere with channel trafficking, including promoting or inhibiting channel forward or backward trafficking, modulating intracellular accumulation, regulating endocytosis and recycling, and so on. The proteins mentioned in Fig. 3 (Golgin-97, AP-1, GRIF-1, SAP-97, ESCRT) are necessary for the forward trafficking, backward trafficking, or recycling of the KIR2.1 channel. Drugs that specifically interfere with these proteins' function with respect to their role in KIR2.1 trafficking, may indirectly help to correct the function of abnormal KIR2.1 channel function. For example, tetramisole showed a high selective affinity with the KIR2.1 channel and increased IK1, one of its mechanisms is promoting KIR2.1 forward trafficking through the upregulation of SAP-97 (Liu et al. 2022).
Drugs enhancing K+ conductance
The potassium conductance of the KIR2.1 channel is primarily determined by its structure and the arrangement of specific amino acids within the channel pore (Fernandes et al. 2022b). Drugs that enhance the conductance of the KIR2.1 channel can increase its preference for K+, potentially allowing more K+ to pass through while blocking or restricting the movement of other ions. Potassium channel openers are a class of drugs that have the potential to increase the conductance of K+. This increase in IK1 may benefit patients who suffer from ATS or HF in the future.
Some other specific channel agonists or inhibitors
There are several KIR2.1 modulators, or at least compounds that include KIR2.1 modulatory behavior amongst other properties. For example, propafenone, flecainide, aldosterone, sildenafil, etc. (Alexandre et al. 2015; Caballero et al. 2010; Gomez et al. 2014; Iijima et al. 2023). These compounds probably will generate a lot of side effects due to their multifunctional characteristics if they work as KIR2.1 modulators. The promising modulators will specifically target the channel without interfering with other channels. Studies showed that zacopride can promote IK1 without interfering with voltage-gated Na+ current, L-type Ca2+ current, transient outward K+ current, sustained outward K+ current, delayed rectifier K+ current, and current generated through Na+–Ca2+ exchanger and Na+–K+ pump (Lin et al. 2020; Liu et al. 2012). Gambogic acid is a specific, slow KIR2.1 inhibitor by changing the K+ channel membrane microenvironment (Zaks-Makhina et al. 2009). ML-133 was reported as a potent specific KIR2.x inhibitor, reducing K+ conductance through the channel by interfering with D172 and I176 on the M2 segment of the channel (Wang et al. 2011). A study in 2019 showed that the Hill coefficient of ML-133 is 2.6 (> 1) meaning that ML133 probably has a cooperative mechanism of action which is still unknown (Sanson et al. 2019). Drugs increasing or decreasing the binding affinity of polyamines or Mg2+ can also be utilized for future therapeutic purposes. The discovery of specific KIR2.1 modulators provides a path for functional studies of IK1. More “next generation” KIR channel modulators which are both potent and specific are needed, to achieve this, employing high-throughput screening of small-molecule libraries and utilizing medicinal chemistry (structure-based drug design) will help (Weaver and Denton 2021).
Nutrigenomics
People have used food and plants as medicines since ancient times, as they know that food and the environment can interfere with an individual’s health conditions (Sales et al. 2014). The emergence of the field of nutrigenomics, which combines genomic science with nutrition, is a direct consequence of elucidating the interactions between genes and nutrients (Sales et al. 2014). Understanding this interaction process could lead to the prescription of specific diets for each individual. Nutrigenomics is a relatively new field in regulating KIR channels, specific diets or variations in nutrient conditions have the potential to influence the expression or function of KIR channels in tissues (Ferreira et al. 2023). Diets rich in cholesterol have been associated with increased membrane cholesterol content, which resulted in a decreased function of KIR2.1 channels (Ferreira et al. 2023; Yuan and Hansen 2023). Diets rich in phosphoinositide or inositol like liver, grains, and legumes could increase the expression level and functions of KIR2.1 channels by altering the levels of PIP2 in cells through the metabolite process (Ferreira et al. 2023). Diets rich in salt interfere with potassium handling, and even though no nutrition-related factors are reported in patients of ATS, special diets that are low in carbohydrates and Na+ were recommended for some cases (Ferreira et al. 2023; Welland et al. 2021). Diets rich in polyamines like cheese, meat, vegetables, etc. show prominent cardioprotective and neuroprotective effects (Madeo et al. 2018; Munoz-Esparza et al. 2019). Diets rich in Mg2+ like vegetables, nuts, seeds, etc. are necessary in some cases, as chronic Mg2+ deficiency could downregulate the expression of the KIR 2.1 channel and cause a reduction of IK1 (Al Alawi et al. 2018; Shimaoka et al. 2020). The coupling between nutrient and KIR channels is complex and can involve multiple mechanisms, more investigations are needed in this field.
Gene therapy
KCNJ2 mutations could cause AST, SQT3, FAF, and maybe some other diseases not currently detected. Gene analysis is already used in part of the cardiovascular diseases workup, it helps to make more accurate diagnoses (Di Toro et al. 2019; Vivekanandam et al. 2022; Xia et al. 2005). Developing gene therapy techniques allows for the direct manipulation of KIR2.1 channel expression or activity in specific tissues. Gene therapy helps to replace the mutant DNA with the wild-type DNA, leading to a normal function of the KIR2.1 channel.
Conclusions
The functional KIR2.1 channel helps to stabilize the resting membrane potential and regulate the excitability of the heart. This channel plays important roles in the maintenance of normal heart rhythm and cell communication. All patients who suffered similar symptoms related to the KCNJ2 gene should be offered a genetic diagnosis, that might further assist in individualized treatment. The development of drugs or gene therapy targeting the KIR2.1 channel is a complex and challenging process. Further research and clinical investigations are necessary to fully understand the complete range of diseases or conditions associated with the KIR2.1 channel.
Data availability
No datasets were generated or analysed during the current study.
Abbreviations
- AP/APD:
-
Action potential/Action potential duration
- AP-1:
-
Adaptor protein 1
- ATS:
-
Anderson-Tawil syndrome
- ASD:
-
Autism spectrum disorder
- CTD:
-
Cytoplasmic domain
- CPVT:
-
Catecholaminergic Polymorphic Ventricular Tachycardia
- CQ:
-
Chloroquine
- ERP:
-
Effective refractory period
- ER:
-
Endoplasmic reticulum
- ESCRT:
-
Endosomal sorting complex required for transport
- FAF/AF:
-
Familial Atrial Fibrillation /Atrial Fibrillation
- GRIF-1:
-
γ-Aminobutyric acid type A receptor interacting factor-1
- GFP:
-
Green fluorescent protein
- GCEP:
-
Gene curation expert panel
- HF:
-
Heart Failure
- IK1 :
-
Inward rectifier potassium current
- KIR2.1, KIR2.2, KIR2.3:
-
Inward rectifier potassium channel
- KWGF:
-
Human embryonic kidney (HEK)-293 cells that stably express C-terminal GFP-tagged murine KIR2.1
- MVB:
-
Multivesicular bodies
- PKA:
-
Protein kinase A
- PKC:
-
Protein kinase C
- PKP4:
-
Plakophilin 4
- PIP2 :
-
Phosphatidylinositol-4,5-bisphosphate
- RMP:
-
Resting membrane potential
- Rac1:
-
Ras-related C3 botulinum toxin substrate 1
- SAP-97:
-
Scaffolding protein
- SQT/LQT:
-
Short QT syndrome / Long QT Syndrome
- TMD:
-
Transmembrane domain
References
Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, Feilotter H, Amenta S, Mazza D, Bikker H, Sturm AC, Garcia J, Ackerman MJ, Hershberger RE, Perez MV, Zareba W, Ware JS, Wilde AAM, Gollob MH (2020) An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 141(6):418–428. https://doi.org/10.1161/CIRCULATIONAHA.119.043132
Aimond F, Alvarez JL, Rauzier JM, Lorente P, Vassort G (1999) Ionic basis of ventricular arrhythmias in remodeled rat heart during long-term myocardial infarction. Cardiovasc Res 42(2):402–415. https://doi.org/10.1016/s0008-6363(99)00070-x
Akar FG, Wu RC, Juang GJ, Tian YL, Burysek M, Disilvestre D, Xiong W, Armoundas AA, Tomaselli GF (2005) Molecular mechanisms underlying K+ current downregulation in canine tachycardia-induced heart failure. Am J Physiol Heart Circ Physiol 288(6):H2887–H2896. https://doi.org/10.1152/ajpheart.00320.2004
Akyuz E, Koklu B, Uner A, Angelopoulou E, Paudel YN (2022) Envisioning the role of inwardly rectifying potassium (Kir) channel in epilepsy. J Neurosci Res 100(2):413–443. https://doi.org/10.1002/jnr.24985
Al Alawi AM, Majoni SW, Falhammar H (2018) Magnesium and Human Health: Perspectives and Research Directions. Int J Endocrinol 2018:9041694. https://doi.org/10.1155/2018/9041694
Alexandre J, Hof T, Puddu PE, Rouet R, Guinamard R, Manrique A, Beygui F, Salle L, Milliez P (2015) Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion. PLoS ONE 10(7):e0132592. https://doi.org/10.1371/journal.pone.0132592
Al-Khatib SM (2023) Atrial Fibrillation. Ann Intern Med. https://doi.org/10.7326/AITC202307180.10.7326/AITC202307180
Ambrosini E, Sicca F, Brignone MS, D’adamo MC, Napolitano C, Servettini I, Moro F, Ruan YF, Guglielmi L, Pieroni S, Servillo G, Lanciotti A, Valvo G, Catacuzzeno L, Franciolini F, Molinari P, Marchese M, Grottesi A, Guerrini R, Santorelli FM, Priori S, Pessia M (2014) Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype. Human Molecular Genetics 23(18):4875–4886. https://doi.org/10.1093/hmg/ddu201
Anumonwo JM, Lopatin AN (2010) Cardiac strong inward rectifier potassium channels. J Mol Cell Cardiol 48(1):45–54. https://doi.org/10.1016/j.yjmcc.2009.08.013
Barajas-Martinez H, Hu D, Ontiveros G, Caceres G, Desai M, Burashnikov E, Scaglione J, Antzelevitch C (2011) Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. Circ Cardiovasc Genet 4(1):51–57. https://doi.org/10.1161/CIRCGENETICS.110.957696
Baronas VA, Kurata HT (2014) Inward rectifiers and their regulation by endogenous polyamines. Front Physiol 5:325. https://doi.org/10.3389/fphys.2014.00325
Barron-Diaz DR, Totomoch-Serra A, Escobar-Cedillo RE, Garcia-Gutierrez A, Reyes-Quintero AE, Villegas Daviran SE, Ibarra-Miramon CB, Marquez MF (2020) Andersen-Tawil Syndrome with High Risk of Sudden Cardiac Death in Four Mexican Patients. Cardiac and Extra-Cardiac Phenotypes. Rev Invest Clin 73(5). https://doi.org/10.24875/RIC.20000310
Basza M, Maciejewski C, Bojanowicz W, Balsam P, Grabowski M, Mitkowski P, Kempa M, Kowalski O, Kalarus Z, Jaguszewski M, Lubinski A, Danilowicz-Szymanowicz L, Szumowski L, Sterlinski M, Koltowski L (2023) Flecainide in clinical practice. Cardiol J 30(3):473–482. https://doi.org/10.5603/CJ.a2023.0018
Bellante F, Legros B, Depondt C, Creteur J, Taccone FS, Gaspard N (2016) Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol 263(4):799–806. https://doi.org/10.1007/s00415-016-8074-7
Bendahhou S, Donaldson MR, Plaster NM, Tristani-Firouzi M, Fu YH, Ptacek LJ (2003) Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. J Biol Chem 278(51):51779–51785. https://doi.org/10.1074/jbc.M310278200
Benjamin EJ, Al-Khatib SM, Desvigne-Nickens P, Alonso A, Djousse L, Forman DE, Gillis AM, Hendriks JML, Hills MT, Kirchhof P, Link MS, Marcus GM, Mehra R, Murray KT, Parkash R, Pina IL, Redline S, Rienstra M, Sanders P, Somers VK, Van Wagoner DR, Wang PJ, Cooper LS, Go AS (2021) Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report. J Am Heart Assoc 10(16):e021566. https://doi.org/10.1161/JAHA.121.021566
Beverley KM, Pattnaik BR (2022) Inward rectifier potassium (Kir) channels in the retina: living our vision. Am J Physiol Cell Physiol 323(3):C772–C782. https://doi.org/10.1152/ajpcell.00112.2022
Bhoelan BS, Stevering CH, Van Der Boog AT, Van Der Heyden MAG (2014) Barium toxicity and the role of the potassium inward rectifier current. Clin Toxicol (Phila) 52(6):584–593. https://doi.org/10.3109/15563650.2014.923903
Bienias P, Kostera-Pruszczyk A, Miszczak-Knecht M, Ciurzynski M, Pruszczyk P (2018) Propafenone is not effective for severe ventricular arrhythmias in Andersen-Tawil syndrome. Arch Med Sci 14(1):248–250. https://doi.org/10.5114/aoms.2016.61010
Binda A, Rivolta I, Villa C, Chisci E, Beghi M, Cornaggia CM, Giovannoni R, Combi R (2018) A Novel KCNJ2 Mutation Identified in an Autistic Proband Affects the Single Channel Properties of Kir2.1. Front Cell Neurosci 12;76. https://doi.org/10.3389/fncel.2018.00076
Boyer SB, Slesinger PA, Jones SV (2009) Regulation of Kir2.1 channels by the Rho-GTPase, Rac1. J Cell Physiol 218(2):385–393. https://doi.org/10.1002/jcp.21610
Buch P, Friberg J, Scharling H, Lange P, Prescott E (2003) Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 21(6):1012–1016. https://doi.org/10.1183/09031936.03.00051502
Caballero R, Dolz-Gaiton P, Gomez R, Amoros I, Barana A, Gonzalez De La Fuente M, Osuna L, Duarte J, Lopez-Izquierdo A, Moraleda I, Galvez E, Sanchez-Chapula JA, Tamargo J, Delpon E (2010) Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification. Proc Natl Acad Sci U S A 107(35):15631–15636. https://doi.org/10.1073/pnas.1004021107
Chang HK, Lee JR, Liu TA, Suen CS, Arreola J, Shieh RC (2010) The extracellular K+ concentration dependence of outward currents through Kir2.1 channels is regulated by extracellular Na+ and Ca2+. J Biol Chem 285(30):23115–23125. https://doi.org/10.1074/jbc.M110.121186
Choi BO, Kim J, Suh BC, Yu JS, Sunwoo IN, Kim SJ, Kim GH, Chung KW (2007) Mutations of KCNJ2 gene associated with Andersen-Tawil syndrome in Korean families. J Hum Genet 52(3):280–283. https://doi.org/10.1007/s10038-006-0100-7
Christophersen IE, Ellinor PT (2016) Genetics of atrial fibrillation: from families to genomes. J Hum Genet 61(1):61–70. https://doi.org/10.1038/jhg.2015.44
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, Mcanulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ (2014) Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129(8):837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119
Crotti L, Odening KE, Sanguinetti MC (2020) Heritable arrhythmias associated with abnormal function of cardiac potassium channels. Cardiovasc Res 116(9):1542–1556. https://doi.org/10.1093/cvr/cvaa068
Cruz FM, Macias A, Moreno-Manuel AI, Gutierrez LK, Vera-Pedrosa ML, Martinez-Carrascoso I, Perez PS, Ruiz Robles JM, Bermudez-Jimenez FJ, Diaz-Agustin A, Martinez De Benito F, Santiago SA, Braza-Boils A, Martin-Martinez M, Gutierrez-Rodriguez M, Bernal JA, Zorio E, Jimenez-Jaimez J, Jalife J (2023) Extracellular cysteine disulfide bond break at Cys122 disrupts PIP (2) -dependent Kir2.1 channel function and leads to arrhythmias in Andersen-Tawil Syndrome. bioRxiv.https://doi.org/10.1101/2023.06.07.544151
Cui M, Cantwell L, Zorn A, Logothetis DE (2021) Kir Channel Molecular Physiology, Pharmacology, and Therapeutic Implications. Handb Exp Pharmacol 267:277–356. https://doi.org/10.1007/164_2021_501
Dago M, Crespo-Garcia T, Camara-Checa A, Rapun J, Rubio-Alarcon M, Marin M, Tamargo J, Caballero R, Delpon E (2022) Empagliflozin and Dapagliflozin Increase Na(+) and Inward Rectifier K(+) Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs). Cells 11(23). https://doi.org/10.3390/cells11233707
Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh BJ, Shen WK, Hammill SC, Packer DL, Olson TM (2003) Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 41(12):2185–2192. https://doi.org/10.1016/s0735-1097(03)00465-0
D’avanzo N, Cheng WW, Doyle DA, Nichols CG (2010) Direct and specific activation of human inward rectifier K+ channels by membrane phosphatidylinositol 4,5-bisphosphate. J Biol Chem 285(48):37129–37132. https://doi.org/10.1074/jbc.C110.186692
De Boer TP, Van Veen TA, Houtman MJ, Jansen JA, Van Amersfoorth SC, Doevendans PA, Vos MA, Van Der Heyden MAG (2006) Inhibition of cardiomyocyte automaticity by electrotonic application of inward rectifier current from Kir2.1 expressing cells. Med Biol Eng Comput 44(7):537–542. https://doi.org/10.1007/s11517-006-0059-8
De Boer TP, Houtman MJC, Compier M, Van Der Heyden MAG (2010a) The mammalian K(IR)2.x inward rectifier ion channel family: expression pattern and pathophysiology. Acta Physiol (Oxf) 199(3):243–256. https://doi.org/10.1111/j.1748-1716.2010.02108.x
De Boer TP, Nalos L, Stary A, Kok B, Houtman MJ, Antoons G, Van Veen TA, Beekman JD, De Groot BL, Opthof T, Rook MB, Vos MA, Van Der Heyden MAG (2010b) The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel. Br J Pharmacol 159(7):1532–1541. https://doi.org/10.1111/j.1476-5381.2010.00658.x
De Git KCG, De Boer TP, Vos MA, Van der Heyden MAG (2013) Cardiac ion channel trafficking defects and drugs. Pharmacol Ther 139(1):24–31. https://doi.org/10.1016/j.pharmthera.2013.03.008
Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, Camous JP, Tournant G, Rendu E, Kyndt F, Haissaguerre M, Bezieau S, Guyomarch B, Le Marec H, Fressart V, Denjoy I, Probst V (2013) Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace 15(12):1805–1811. https://doi.org/10.1093/europace/eut160
De Los Monteros LGE, Martinez F, Cruz FM, Moreno-Manuel AI, Sanchez P, Vera-Pedrosa ML, Martinez-Carrascoso I, Bermudez-Jimenez F, Macias A, Jalife J (2022) Three dimensional modelling of mutant Kir2.1 channel PIP2 interactions help stratify arrhythmia severity in Andersen Tawil syndrome type 1. Eur Heart 43;365–365. <Go to ISI>://WOS:000894947902464
Deo M, Ruan Y, Pandit SV, Shah K, Berenfeld O, Blaufox A, Cerrone M, Noujaim SF, Denegri M, Jalife J, Priori SG (2013) KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc Natl Acad Sci U S A 110(11):4291–4296. https://doi.org/10.1073/pnas.1218154110
Dewi IP, Dharmadjati BB (2020) Short QT syndrome: The current evidences of diagnosis and management. J Arrhythm 36(6):962–966. https://doi.org/10.1002/joa3.12439
Dhamoon AS, Jalife J (2005) The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm 2(3):316–324. https://doi.org/10.1016/j.hrthm.2004.11.012
Di Toro A, Giuliani L, Favalli V, Di Giovannantonio M, Smirnova A, Grasso M, Arbustini E (2019) Genetics and clinics: current applications, limitations, and future developments. Eur Heart J Suppl 21(Suppl B):B7–B14. https://doi.org/10.1093/eurheartj/suz048
Dobrev D, Wettwer E, Kortner A, Knaut M, Schuler S, Ravens U (2002) Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res 54(2):397–404. https://doi.org/10.1016/s0008-6363(01)00555-7
Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S, Akao M, Takahashi Y, Kimura T, Horie M (2011) A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome. Circ Cardiovasc Genet 4(3):253–260. https://doi.org/10.1161/CIRCGENETICS.110.958157
Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, Suarez WA, Cobo AM, Poza JJ, Behr E, Wagstaff J, Szepetowski P, Pereira S, Mozaffar T, Escolar DM, Fu YH, Ptacek LJ (2003) PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 60(11):1811–1816. https://doi.org/10.1212/01.wnl.0000072261.14060.47
Du X, Zhang H, Lopes C, Mirshahi T, Rohacs T, Logothetis DE (2004) Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators. J Biol Chem 279(36):37271–37281. https://doi.org/10.1074/jbc.M403413200
Du J, Li Z, Wang X, Li J, Liu D, Wang X, Wei J, Ma S, Zhang Y, Hou Y (2020) Long noncoding RNA TCONS-00106987 promotes atrial electrical remodelling during atrial fibrillation by sponging miR-26 to regulate KCNJ2. J Cell Mol Med 24(21):12777–12788. https://doi.org/10.1111/jcmm.15869
Du C, Rasmusson RL, Bett GC, Franks B, Zhang H, Hancox JC (2021) Investigation of the Effects of the Short QT Syndrome D172N Kir2.1 Mutation on Ventricular Action Potential Profile Using Dynamic Clamp. Front Pharmacol 12;794620. https://doi.org/10.3389/fphar.2021.794620
Elnakish MT, Canan BD, Kilic A, Mohler PJ, Janssen PM (2017) Effects of zacopride, a moderate I(K1) channel agonist, on triggered arrhythmia and contractility in human ventricular myocardium. Pharmacol Res 115:309–318. https://doi.org/10.1016/j.phrs.2016.11.033
Fauconnier J, Lacampagne A, Rauzier JM, Vassort G, Richard S (2005) Ca2+-dependent reduction of IK1 in rat ventricular cells: a novel paradigm for arrhythmia in heart failure? Cardiovasc Res 68(2):204–212. https://doi.org/10.1016/j.cardiores.2005.05.024
Fernandes CAH, Venien-Bryan C, Fagnen C, Zuniga D (2022a) Cryo-EM structure of the human inward-rectifier potassium 2.1 channel (Kir2.1). https://doi.org/10.2210/pdb7ZDZ/pdb
Fernandes CAH, Zuniga D, Fagnen C, Kugler V, Scala R, Pehau-Arnaudet G, Wagner R, Perahia D, Bendahhou S, Venien-Bryan C (2022b) Cryo-electron microscopy unveils unique structural features of the human Kir2.1 channel. Sci Adv 8(38):eabq8489. https://doi.org/10.1126/sciadv.abq8489
Fernlund E, Lundin C, Hertervig E, Kongstad O, Alders M, Platonov P (2013) Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome. Ann Noninvasive Electrocardiol 18(5):471–478. https://doi.org/10.1111/anec.12074
Ferreira G, Santander A, Cardozo R, Chavarria L, Dominguez L, Mujica N, Benitez M, Sastre S, Sobrevia L, Nicolson GL (2023) Nutrigenomics of inward rectifier potassium channels. Biochim Biophys Acta Mol Basis Dis 1869(7):166803. https://doi.org/10.1016/j.bbadis.2023.166803
Ferrer T, Ponce-Balbuena D, Lopez-Izquierdo A, Arechiga-Figueroa IA, De Boer TP, Van Der Heyden MAG, Sanchez-Chapula JA (2011) Carvedilol inhibits Kir2.3 channels by interference with PIP(2)-channel interaction. Eur J Pharmacol 668(1–2):72–77. https://doi.org/10.1016/j.ejphar.2011.05.067
Ficker E, Taglialatela M, Wible BA, Henley CM, Brown AM (1994) Spermine and spermidine as gating molecules for inward rectifier K+ channels. Science 266(5187):1068–1072. https://doi.org/10.1126/science.7973666
Fujiwara Y, Kubo Y (2006) Functional roles of charged amino acid residues on the wall of the cytoplasmic pore of Kir2.1. J Gen Physiol 127(4):401–419. https://doi.org/10.1085/jgp.200509434
Fukumura S, Yamauchi K, Kawanabe A, Yamamoto A, Nakaza M, Kubota T, Kato S, Sasaki R, Okamura Y, Takahashi MP (2019) Functional analysis of a double-point mutation in the KCNJ2 gene identified in a family with Andersen-Tawil syndrome. J Neurol Sci 407:116521. https://doi.org/10.1016/j.jns.2019.116521
Gada KD, Logothetis DE (2022) PKC regulation of ion channels: The involvement of PIP(2). J Biol Chem 298(6):102035. https://doi.org/10.1016/j.jbc.2022.102035
Gadsby DC (2009) Ion channels versus ion pumps: the principal difference, in principle. Nat Rev Mol Cell Biol 10(5):344–352. https://doi.org/10.1038/nrm2668
Gao J, Zhao Y, Wang Y, Xin J, Cui J, Ma S, Lu F, Qin L, Yu X (2015) Anti-arrhythmic effect of acupuncture pretreatment in the rats subjected to simulative global ischemia and reperfusion–involvement of intracellular Ca2+ and connexin 43. BMC Complement Altern Med 15:5. https://doi.org/10.1186/s12906-015-0521-y
Gilles O (2022) K(+) -independent Kir blockade by external Cs(+) and Ba(2). Physiol Rep 10(5):15200. https://doi.org/10.14814/phy2.15200
Gillet L, Rougier JS, Shy D, Sonntag S, Mougenot N, Essers M, Shmerling D, Balse E, Hatem SN, Abriel H (2015) Cardiac-specific ablation of synapse-associated protein SAP97 in mice decreases potassium currents but not sodium current. Heart Rhythm 12(1):181–192. https://doi.org/10.1016/j.hrthm.2014.09.057
Giovannardi S, Forlani G, Balestrini M, Bossi E, Tonini R, Sturani E, Peres A, Zippel R (2002) Modulation of the inward rectifier potassium channel IRK1 by the Ras signaling pathway. J Biol Chem 277(14):12158–12163. https://doi.org/10.1074/jbc.M110466200
Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, Bukowska A, Goette A, Nattel S, Hohnloser SH, Ehrlich JR (2009) Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 6(12):1802–1809. https://doi.org/10.1016/j.hrthm.2009.08.035
Gomez R, Caballero R, Barana A, Amoros I, De Palm SH, Matamoros M, Nunez M, Perez-Hernandez M, Iriepa I, Tamargo J, Delpon E (2014) Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. Cardiovasc Res 104(2):337–346. https://doi.org/10.1093/cvr/cvu203
Goversen B, De Boer TP, Van Der Heyden MAG (2016) Commentary: Reciprocal Modulation of IK1-INa Extends Excitability in Cardiac Ventricular Cells. Front Physiol 7:647. https://doi.org/10.3389/fphys.2016.00647
Gramegna A, Contarini M, Bindo F, Aliberti S, Blasi F (2021) Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Curr Opin Pharmacol 57:81–88. https://doi.org/10.1016/j.coph.2021.01.001
Grider MH, Jessu R, Kabir R (2023) Physiology, Action Potential. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/30844170. Accessed 8 May 2023
Grishin A, Li H, Levitan ES, Zaks-Makhina E (2006) Identification of gamma-aminobutyric acid receptor-interacting factor 1 (TRAK2) as a trafficking factor for the K+ channel Kir2.1. J Biol Chem 281(40):30104–30111. https://doi.org/10.1074/jbc.M602439200
Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P (2000) Idiopathic short QT interval: a new clinical syndrome? Cardiology 94(2):99–102. https://doi.org/10.1159/000047299
Gutierrez LK, Moreno-Manuel AI, Jalife J (2024) The Kir2.1-Na(V)1.5 Channelosome and its role in Arrhythmias in Inheritable Cardiac Diseases. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.01.017.10.1016/j.hrthm.2024.01.017
Hager NA, Mcatee CK, Lesko MA, O'donnell AF (2021) Inwardly Rectifying Potassium Channel Kir2.1 and its "Kir-ious" Regulation by Protein Trafficking and Roles in Development and Disease. Front Cell Dev Biol 9;796136. https://doi.org/10.3389/fcell.2021.796136
Hancox JC, Du CY, Butler A, Zhang Y, Dempsey CE, Harmer SC, Zhang H (2023) Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome. Philos Trans R Soc Lond B Biol Sci 378(1879):20220165. https://doi.org/10.1098/rstb.2022.0165
Handklo-Jamal R, Meisel E, Yakubovich D, Vysochek L, Beinart R, Glikson M, Mcmullen JR, Dascal N, Nof E, Oz S (2020a) Andersen-Tawil Syndrome Is Associated With Impaired PIP(2) Regulation of the Potassium Channel Kir2.1. Front Pharmacol 11:672. https://doi.org/10.3389/fphar.2020.00672
Handklo-Jamal R, Meisel E, Yakubovich D, Vysochek L, Beinart R, Glikson M, Mcmullen JR, Dascal N, Nof E, Oz S (2020b) Andersen-Tawil Syndrome Is Associated With Impaired PIP2 Regulation of the Potassium Channel Kir2.1. Front Pharmacol 11. https://doi.org/10.3389/fphar.2020.00672
Hattori T, Makiyama T, Akao M, Ehara E, Ohno S, Iguchi M, Nishio Y, Sasaki K, Itoh H, Yokode M, Kita T, Horie M, Kimura T (2012) A novel gain-of-function KCNJ2 mutation associated with short-QT syndrome impairs inward rectification of Kir2.1 currents. Cardiovasc Res 93(4):666–673. https://doi.org/10.1093/cvr/cvr329
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y (2010) Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 90(1):291–366. https://doi.org/10.1152/physrev.00021.2009
Hii JT, Duff HJ, Burgess ED (1991) Clinical pharmacokinetics of propafenone. Clin Pharmacokinet 21(1):1–10. https://doi.org/10.2165/00003088-199121010-00001
Hofherr A, Fakler B, Klocker N (2005) Selective Golgi export of Kir2.1 controls the stoichiometry of functional Kir2.x channel heteromers. J Cell Sci 118(Pt 9):1935–1943. https://doi.org/10.1242/jcs.02322
Husti Z, Varro A, Baczko I (2021) Arrhythmogenic Remodeling in the Failing Heart. Cells 10(11). https://doi.org/10.3390/cells10113203
Iijima A, Svecova O, Hosek J, Kula R, Bebarova M (2023) Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations: Inhibition potentiated by low Ba(2). Front Pharmacol 14:1136272. https://doi.org/10.3389/fphar.2023.1136272
Imoto Y, Ehara T, Matsuura H (1987) Voltage- and time-dependent block of IK1 underlying Ba2+-induced ventricular automaticity. Am J Physiol 252(2 Pt 2):H325-333. https://doi.org/10.1152/ajpheart.1987.252.2.H325
Ishihara K (2018) External K(+) dependence of strong inward rectifier K(+) channel conductance is caused not by K(+) but by competitive pore blockade by external Na(+). J Gen Physiol 150(7):977–989. https://doi.org/10.1085/jgp.201711936
Ishihara K, Ehara T (2004) Two modes of polyamine block regulating the cardiac inward rectifier K+ current IK1 as revealed by a study of the Kir2.1 channel expressed in a human cell line. J Physiol 556(Pt 1):61–78. https://doi.org/10.1113/jphysiol.2003.055434
Ishihara K, Sarai N, Asakura K, Noma A, Matsuoka S (2009) Role of Mg(2+) block of the inward rectifier K(+) current in cardiac repolarization reserve: A quantitative simulation. J Mol Cell Cardiol 47(1):76–84. https://doi.org/10.1016/j.yjmcc.2009.03.008
Ishihara K, Hiraoka M, Ochi R (1996) The tetravalent organic cation spermine causes the gating of the IRK1 channel expressed in murine fibroblast cells. J Physiol 491 ( Pt 2)(Pt 2), 367–381. https://doi.org/10.1113/jphysiol.1996.sp021222
Jansen JA, De Boer TP, Wolswinkel R, Van Veen TA, Vos MA, Van Rijen HV, Van Der Heyden MAG (2008) Lysosome mediated Kir2.1 breakdown directly influences inward rectifier current density. Biochem Biophys Res Commun 367(3):687–692. https://doi.org/10.1016/j.bbrc.2007.12.168
Ji Y, Varkevisser R, Opacic D, Bossu A, Kuiper M, Beekman JDM, Yang S, Khan AP, Dobrev D, Voigt N, Wang MZ, Verheule S, Vos MA, Van Der Heyden MAG (2017a) The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models. Br J Pharmacol 174(15):2576–2590. https://doi.org/10.1111/bph.13869
Ji Y, Veldhuis MG, Zandvoort J, Romunde FL, Houtman MJC, Duran K, Van Haaften G, Zangerl-Plessl EM, Takanari H, Stary-Weinzinger A, Van Der Heyden MAG (2017b) PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function K(IR)2.1 channels, but increases channel protein expression. J Biomed Sci 24(1):44. https://doi.org/10.1186/s12929-017-0352-x
Jian K, Li C, Hancox JC, Zhang HG (2022) Pro-Arrhythmic Effects of Discontinuous Conduction at the Purkinje Fiber-Ventricle Junction Arising From Heart Failure-Induced Ionic Remodeling - Insights From Computational Modelling. Frontiers in Physiology, 13. ARTN 877428. https://doi.org/10.3389/fphys.2022.877428
Jongsma HJ, Wilders R (2001) Channelopathies: Kir2.1 mutations jeopardize many cell functions. Curr Biol 11(18):R747-750. https://doi.org/10.1016/s0960-9822(01)00437-7
Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R (2002) Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology 59(3):466. https://doi.org/10.1212/wnl.59.3.466
Kaab S, Nuss HB, Chiamvimonvat N, O’rourke B, Pak PH, Kass DA, Marban E, Tomaselli GF (1996) Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 78(2):262–273. https://doi.org/10.1161/01.res.78.2.262
Kalscheur MM, Vaidyanathan R, Orland KM, Abozeid S, Fabry N, Maginot KR, January CT, Makielski JC, Eckhardt LL (2014) KCNJ2 mutation causes an adrenergic-dependent rectification abnormality with calcium sensitivity and ventricular arrhythmia. Heart Rhythm 11(5):885–894. https://doi.org/10.1016/j.hrthm.2014.02.015
Karschin A (1999) G Protein Regulation of Inwardly Rectifying K(+) Channels. News Physiol Sci 14:215–220. https://doi.org/10.1152/physiologyonline.1999.14.5.215
Katz B (1949) Les constantes electriques de la membrane du muscle. Arch Sci Physiol 2:285–299
Kim JB (2014) Channelopathies. Korean. J Pediatr 57(1):1–18. https://doi.org/10.3345/kjp.2014.57.1.1
Kim DY, Uhm JS, Kim M, Kim IS, Jin MN, Yu HT, Kim TH, Kim JY, Joung B, Pak HN, Lee MH (2021) Long-term prognosis of short QT interval in Korean patients: a multicenter retrospective cohort study. BMC Cardiovasc Disord 21(1):17. https://doi.org/10.1186/s12872-020-01824-3
Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J, Ohno S, Makiyama T, Miyamoto A, Naiki N, Wang Q, Xie Y, Suzuki T, Tateno S, Nakamura Y, Zang WJ, Ito M, Matsuura H, Horie M (2012) Phenotype variability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet 5(3):344–353. https://doi.org/10.1161/CIRCGENETICS.111.962316
Kirkton RD, Bursac N (2011) Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies. Nat Commun 2:300. https://doi.org/10.1038/ncomms1302
Koepple C, Scherer D, Seyler C, Scholz E, Thomas D, Katus HA, Zitron E (2017) Dual Mechanism for Inhibition of Inwardly Rectifying Kir2.x Channels by Quinidine Involving Direct Pore Block and PIP(2)-interference. J Pharmacol Exp Ther 361(2):209–218. https://doi.org/10.1124/jpet.116.238287
Kokunai Y, Nakata T, Furuta M, Sakata S, Kimura H, Aiba T, Yoshinaga M, Osaki Y, Nakamori M, Itoh H, Sato T, Kubota T, Kadota K, Shindo K, Mochizuki H, Shimizu W, Horie M, Okamura Y, Ohno K, Takahashi MP (2014) A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. Neurology 82(12):1058–1064. https://doi.org/10.1212/WNL.0000000000000239
Kolb AR, Needham PG, Rothenberg C, Guerriero CJ, Welling PA, Brodsky JL (2014) ESCRT regulates surface expression of the Kir2.1 potassium channel. Mol Biol Cell 25(2):276–289. https://doi.org/10.1091/mbc.E13-07-0394
Korte SM, Van Der Heyden MAG (2017) Preventing Publication of Falsified and Fabricated Data: Roles of Scientists, Editors, Reviewers, and Readers. J Cardiovasc Pharmacol 69(2):65–70. https://doi.org/10.1097/FJC.0000000000000443
Kostera-Pruszczyk A, Potulska-Chromik A, Pruszczyk P, Bieganowska K, Miszczak-Knecht M, Bienias P, Szczaluba K, Lee HY, Quinn E, Ploski R, Kaminska A, Ptacek LJ (2015) Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement. Muscle Nerve 51(2):192–196. https://doi.org/10.1002/mus.24293
Kubo Y (1996) Two aspects of the inward rectification mechanism. Effects of cytoplasmic blockers and extracellular K+ on the inward rectifier K+ channel. Jpn Heart J 37(5):631–641. https://doi.org/10.1536/ihj.37.631
Kubo Y, Murata Y (2001) Control of rectification and permeation by two distinct sites after the second transmembrane region in Kir2.1 K+ channel. J Physiol 531(Pt 3):645–660. https://doi.org/10.1111/j.1469-7793.2001.0645h.x
Kubo Y, Baldwin TJ, Jan YN, Jan LY (1993) Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 362(6416):127–133. https://doi.org/10.1038/362127a0
Lau DH, Nattel S, Kalman JM, Sanders P (2017) Modifiable Risk Factors and Atrial Fibrillation. Circulation 136(6):583–596. https://doi.org/10.1161/CIRCULATIONAHA.116.023163
Le Tanno P, Folacci M, Revilloud J, Faivre L, Laurent G, Pinson L, Amedro P, Millat G, Janin A, Vivaudou M, Roux-Buisson N, Faure J (2021) Characterization of Loss-Of-Function KCNJ2 Mutations in Atypical Andersen Tawil Syndrome. Front Genet 12:773177. https://doi.org/10.3389/fgene.2021.773177
Lee DS, Chen JH, Lundy DJ, Liu CH, Hwang SM, Pabon L, Shieh RC, Chen CC, Wu SN, Yan YT, Lee ST, Chiang PM, Chien S, Murry CE, Hsieh PC (2015) Defined MicroRNAs Induce Aspects of Maturation in Mouse and Human Embryonic-Stem-Cell-Derived Cardiomyocytes. Cell Rep 12(12):1960–1967. https://doi.org/10.1016/j.celrep.2015.08.042
Li G, Dong M (2010) Revisit of the Cardiac Inward Rectifier Potassium Current IK1. Open Circ Vasc J 3;95-102
Li C, Yang Y (2023) Advancements in the study of inward rectifying potassium channels on vascular cells. Channels (austin) 17(1):2237303. https://doi.org/10.1080/19336950.2023.2237303
Li GR, Lau CP, Leung TK, Nattel S (2004) Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. Heart Rhythm 1(4):460–468. https://doi.org/10.1016/j.hrthm.2004.06.003
Li J, Lu S, Liu Y, Pang C, Chen Y, Zhang S, Yu H, Long M, Zhang H, Logothetis DE, Zhan Y, An H (2015) Identification of the Conformational transition pathway in PIP2 Opening Kir Channels. Sci Rep 5:11289. https://doi.org/10.1038/srep11289
Li ZR, He QF, Wu CY, Chen LL, Bi FF, Zhou YH, Shan HL (2019) Apelin shorten QT interval by inhibiting Kir2.1/I-K1 via a PI3K way in acute myocardial infarction. Biochem Biophys Res Commun 517(2):272–277. https://doi.org/10.1016/j.bbrc.2019.07.041
Li DL, Cox ZL, Richardson TD, Kanagasundram AN, Saavedra PJ, Shen ST, Montgomery JA, Murray KT, Roden DM, Stevenson WG (2021a) Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal. JACC Clin Electrophysiol 7(10):1254–1263. https://doi.org/10.1016/j.jacep.2021.03.024
Li J, Li Y, Liu Y, Yu H, Xu N, Huang D, Xue Y, Li S, Chen H, Liu J, Li Q, Zhao Y, Zhang R, Xue H, Sun Y, Li M, Li P, Liu M, Zhang Z, Li X, Du W, Wang N, Yang B (2021b) Fibroblast Growth Factor 2.1 Ameliorates Na(V)15 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes. Front PhLopez-Izquierdo A, Arecarmacol 12:715466. https://doi.org/10.3389/fphar.2021.715466
Li E, Loen V, Van Ham WB, Kool W, Van Der Heyden MAG, Takanari H (2022) Quantitative analysis of the cytoskeleton’s role in inward rectifier KIR2.1 forward and backward trafficking. Front Physiol 12:812572. https://doi.org/10.3389/fphys.2021.812572
Li E, Kool W, Woolschot L, Van Der Heyden MAG (2023) Chronic Propafenone Application Increases Functional K(IR)2.1 Expression In Vitro. Pharmaceuticals (Basel) 16(3). https://doi.org/10.3390/ph16030404
Lin Y, Li J, Zhu B, Liu Q, Bai X, Chang B, Guo Y, Feng Q, Li X, Wu B, Cao J (2020) Zacopride Exerts an Antiarrhythmic Effect by Specifically Stimulating the Cardiac Inward Rectifier Potassium Current in Rabbits: Exploration of a New Antiarrhythmic Strategy. Curr Pharm Des 26(44):5746–5754. https://doi.org/10.2174/1381612826666200701135508
Liu TA, Chang HK, Shieh RC (2011) Extracellular K+ elevates outward currents through Kir2.1 channels by increasing single-channel conductance. Biochim Biophys Acta 1808(6):1772–1778. https://doi.org/10.1016/j.bbamem.2011.02.016
Liu QH, Li XL, Xu YW, Lin YY, Cao JM, Wu BW (2012) A novel discovery of IK1 channel agonist: zacopride selectively enhances IK1 current and suppresses triggered arrhythmias in the rat. J Cardiovasc Pharmacol 59(1):37–48. https://doi.org/10.1097/FJC.0b013e3182350bcc
Liu Q, Sun J, Zhang L, Xu Y, Wu B, Cao J (2021) The Agonist of Inward Rectifier Potassium Channel (I(K1)) Attenuates Rat Reperfusion Arrhythmias Linked to CaMKII Signaling. Int Heart J 62(6):1348–1357. https://doi.org/10.1536/ihj.21-379
Liu Q, Sun J, Dong Y, Li P, Wang J, Wang Y, Xu Y, Tian X, Wu B, He P, Yu Q, Lu X, Cao J (2022) Tetramisole is a new I(K1) channel agonist and exerts I(K1) -dependent cardioprotective effects in rats. Pharmacol Res Perspect 10(4):e00992. https://doi.org/10.1002/prp2.992
Lopatin AN, Nichols CG (2001) Inward rectifiers in the heart: an update on I(K1). J Mol Cell Cardiol 33(4):625–638. https://doi.org/10.1006/jmcc.2001.1344
Lopatin AN, Makhina EN, Nichols CG (1994) Potassium channel block by cytoplasmic polyamines as the mechanism of intrinsic rectification. Nature 372(6504):366–369. https://doi.org/10.1038/372366a0
Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE (2002) Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron 34(6):933–944. https://doi.org/10.1016/s0896-6273(02)00725-0
Lopez-Izquierdo A, Ponce-Balbuena D, Ferrer T, Rodriguez-Menchaca AA, Sanchez-Chapula JA (2010) Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism. Eur J Pharmacol 638(1–3):33–41. https://doi.org/10.1016/j.ejphar.2010.04.026
Lopez-Izquierdo A, Arechiga-Figueroa IA, Moreno-Galindo EG, Ponce-Balbuena D, Rodriguez-Martinez M, Ferrer-Villada T, Rodriguez-Menchaca AA, Van Der Heyden MAG, Sanchez-Chapula JA (2011a) Mechanisms for Kir channel inhibition by quinacrine: acute pore block of Kir2.x channels and interference in PIP2 interaction with Kir2.x and Kir6.2 channels. Pflugers Arch 462(4):505–517. https://doi.org/10.1007/s00424-011-0995-5
Lopez-Izquierdo A, Ponce-Balbuena D, Moreno-Galindo EG, Arechiga-Figueroa IA, Rodriguez-Martinez M, Ferrer T, Rodriguez-Menchaca AA, Sanchez-Chapula JA (2011b) The Antimalarial Drug Mefloquine Inhibits Cardiac Inward Rectifier K+ Channels: Evidence for Interference in PIP2-Channel Interaction. J Cardiovasc Pharmacol 57(4):407–415. https://doi.org/10.1097/FJC.0b013e31820b7c03
Lu T, Zhu YG, Yang J (1999) Cytoplasmic amino and carboxyl domains form a wide intracellular vestibule in an inwardly rectifying potassium channel. Proc Natl Acad Sci U S A 96(17):9926–9931. https://doi.org/10.1073/pnas.96.17.9926
Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, Lin H, Xiao L, Maguy A, Qi XY, Li Y, Gao X, Dong D, Zhang Y, Bai Y, Ai J, Sun L, Lu H, Luo XY, Wang Z, Lu Y, Yang B, Nattel S (2013) MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 123(5):1939–1951. https://doi.org/10.1172/JCI62185
Luo C, Wang K, Zhang H (2017a) Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles. Physiol Meas 38(10):1859–1873. https://doi.org/10.1088/1361-6579/aa8695
Luo C, Wang K, Zhang H (2017b) Modelling the effects of chloroquine on KCNJ2-linked short QT syndrome. Oncotarget 8(63):106511–106526. https://doi.org/10.18632/oncotarget.22490
Lurtz MM, Louis CF (2007) Intracellular calcium regulation of connexin43. Am J Physiol Cell Physiol 293(6):C1806-1813. https://doi.org/10.1152/ajpcell.00630.2006
Ma D, Zerangue N, Lin YF, Collins A, Yu M, Jan YN, Jan LY (2001) Role of ER export signals in controlling surface potassium channel numbers. Science 291(5502):316–319. https://doi.org/10.1126/science.291.5502.316
Ma D, Taneja TK, Hagen BM, Kim BY, Ortega B, Lederer WJ, Welling PA (2011) Golgi export of the Kir2.1 channel is driven by a trafficking signal located within its tertiary structure. Cell 145(7):1102–1115. https://doi.org/10.1016/j.cell.2011.06.007
Ma K, Ma G, Guo Z, Liu G, Liang W (2021) Regulatory mechanism of calcium/calmodulin-dependent protein kinase II in the occurrence and development of ventricular arrhythmia (Review). Exp Ther Med 21(6):656. https://doi.org/10.3892/etm.2021.10088
Macías Á, González-Guerra A, Moreno-Manuel AI, Cruz FM, Gutiérrez LK, García-Quintáns N, Roche-Molina M, Bermúdez-Jiménez F, Andrés V, Vera-Pedrosa ML, Martínez-Carrascoso I, Jalife JABJ (2022) Kir2.1 dysfunction at the sarcolemma and the sarcoplasmic reticulum causes arrhythmias in a mouse model of Andersen-Tawil syndrome type 1. Nature Cardiovascular Research 1:900–917. https://doi.org/10.1038/s44161-022-00145-2
Madeo F, Eisenberg T, Pietrocola F, Kroemer G (2018) Spermidine in health and disease. Science 359(6374). https://doi.org/10.1126/science.aan2788
Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR (2020) The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Curr Pharm Des 26(35):4467–4485. https://doi.org/10.2174/1381612826666200707132920
Maruyama M, Lin SF, Xie Y, Chua SK, Joung B, Han S, Shinohara T, Shen MJ, Qu Z, Weiss JN, Chen PS (2011) Genesis of phase 3 early afterdepolarizations and triggered activity in acquired long-QT syndrome. Circ Arrhythm Electrophysiol 4(1):103–111. https://doi.org/10.1161/CIRCEP.110.959064
Matamoros M, Perez-Hernandez M, Guerrero-Serna G, Amoros I, Barana A, Nunez M, Ponce-Balbuena D, Sacristan S, Gomez R, Tamargo J, Caballero R, Jalife J, Delpon E (2016) Nav1.5 N-terminal domain binding to alpha1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels. Cardiovasc Res 110(2):279–290. https://doi.org/10.1093/cvr/cvw009
Matsuda H, Cruz Jdos S (1993) Voltage-dependent block by internal Ca2+ ions of inwardly rectifying K+ channels in guinea-pig ventricular cells. J Physiol 470:295–311. https://doi.org/10.1113/jphysiol.1993.sp019859
Mazzanti M, Defelice LJ (1990) Ca modulates outward current through IK1 channels. J Membr Biol 116(1):41–45. https://doi.org/10.1007/BF01871670
Milstein ML, Musa H, Balbuena DP, Anumonwo JM, Auerbach DS, Furspan PB, Hou L, Hu B, Schumacher SM, Vaidyanathan R, Martens JR, Jalife J (2012) Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia. Proc Natl Acad Sci USA 109(31):E2134-2143. https://doi.org/10.1073/pnas.1109370109
Moreno-Manuel AI, Gutierrez LK, Vera-Pedrosa ML, Cruz FM, Bermudez-Jimenez FJ, Martinez-Carrascoso I, Sanchez-Perez P, Macias A, Jalife J (2023) Molecular stratification of arrhythmogenic mechanisms in the Andersen Tawil syndrome. Cardiovasc Res 119(4):919–932. https://doi.org/10.1093/cvr/cvac118
Munoz-Esparza NC, Latorre-Moratalla ML, Comas-Baste O, Toro-Funes N, Veciana-Nogues MT, Vidal-Carou MC (2019) Polyamines in Food Front Nutr 6:108. https://doi.org/10.3389/fnut.2019.00108
Nagy N, Marton Z, Kiss L, Varro A, Nanasi PP, Toth A (2011) Role of Ca(2)+-sensitive K+ currents in controlling ventricular repolarization: possible implications for future antiarrhytmic drug therapy. Curr Med Chem 18(24):3622–3639. https://doi.org/10.2174/092986711796642463
Nagy N, Acsai K, Kormos A, Sebok Z, Farkas AS, Jost N, Nanasi PP, Papp JG, Varro A, Toth A (2013) [Ca(2)(+)] i-induced augmentation of the inward rectifier potassium current (IK1) in canine and human ventricular myocardium. Pflugers Arch 465(11):1621–1635. https://doi.org/10.1007/s00424-013-1309-x
Nguyen D, Ferns SJ (2018) Asymptomatic ventricular tachycardia: diagnostic pitfalls of Andersen-Tawil syndrome-a case report. Eur Heart J Case Rep 2(3):yty083. https://doi.org/10.1093/ehjcr/yty083
Nguyen HL, Pieper GH, Wilders R (2013) Andersen-Tawil syndrome: clinical and molecular aspects. Int J Cardiol 170(1):1–16. https://doi.org/10.1016/j.ijcard.2013.10.010
Nichols CG, Lee SJ (2018) Polyamines and potassium channels: A 25-year romance. J Biol Chem 293(48):18779–18788. https://doi.org/10.1074/jbc.TM118.003344
Nichols CG, Lopatin AN (1997) Inward rectifier potassium channels. Annu Rev Physiol 59:171–191. https://doi.org/10.1146/annurev.physiol.59.1.171
Noujaim SF, Stuckey JA, Ponce-Balbuena D, Ferrer-Villada T, Lopez-Izquierdo A, Pandit S, Calvo CJ, Grzeda KR, Berenfeld O, Chapula JA, Jalife J (2010) Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J 24(11):4302–4312. https://doi.org/10.1096/fj.10-163246
Obeyesekere MN, Klein GJ, Conacher S, Krahn AD (2011) KCNJ2 variant of unknown significance reclassified as long QT syndrome causing ventricular fibrillation. Can J Cardiol 27(6), 870 e811–873 DOI: https://doi.org/10.1016/j.cjca.2011.05.004
Panama BK, Mclerie M, Lopatin AN (2007) Heterogeneity of IK1 in the mouse heart. Am J Physiol Heart Circ Physiol 293(6):H3558-3567. https://doi.org/10.1152/ajpheart.00419.2007
Panama BK, Mclerie M, Lopatin AN (2010) Functional consequences of Kir2.1/Kir2.2 subunit heteromerization. Pflugers Arch 460(5):839–849. https://doi.org/10.1007/s00424-010-0864-7
Park SS, Ponce-Balbuena D, Kuick R, Guerrero-Serna G, Yoon J, Mellacheruvu D, Conlon KP, Basrur V, Nesvizhskii AI, Jalife J, Rual JF (2020) Kir2.1 Interactome Mapping Uncovers PKP4 as a Modulator of the Kir2.1-Regulated Inward Rectifier Potassium Currents. Mol Cell Proteomics 19(9):1436–1449. https://doi.org/10.1074/mcp.RA120.002071
Pennefather P, Oliva C, Mulrine N (1992) Origin of the potassium and voltage dependence of the cardiac inwardly rectifying K-current (IK1). Biophys J 61(2):448–462. https://doi.org/10.1016/S0006-3495(92)81850-7
Perez-Hernandez M, Matamoros M, Alfayate S, Nieto-Marin P, Utrilla RG, Tinaquero D, De Andres R, Crespo T, Ponce-Balbuena D, Willis BC, Jimenez-Vazquez EN., Guerrero-Serna G, Da Rocha AM, Campbell K, Herron TJ, Diez-Guerra FJ, Tamargo J, Jalife J, Caballero R, Delpon E (2018) Brugada syndrome trafficking-defective Nav15 channels can trap cardiac Kir2.1/2.2 channels. JCI Insight 3(18). https://doi.org/10.1172/jci.insight.96291
Perez-Riera AR, Barbosa-Barros R, Samesina N, Pastore CA, Scanavacca M, Daminello-Raimundo R, De Abreu LC, Nikus K, Brugada P (2021) Andersen-Tawil Syndrome: A Comprehensive Review. Cardiol Rev 29(4):165–177. https://doi.org/10.1097/CRD.0000000000000326
Ponce-Balbuena D, Lopez-Izquierdo A, Ferrer T, Rodriguez-Menchaca AA, Arechiga-Figueroa IA, Sanchez-Chapula JA (2009) Tamoxifen Inhibits Inward Rectifier K+ 2x Family of Inward Rectifier Channels by Interfering with Phosphatidylinositol 4,5-Bisphosphate-Channel Interactions. J Pharmacol Exp Ther 331(2):563–573. https://doi.org/10.1124/jpet.109.156075
Ponce-Balbuena D, Guerrero-Serna G, Valdivia CR, Caballero R, Diez-Guerra FJ, Jimenez-Vazquez EN, Ramirez RJ, Monteiro Da Rocha A, Herron TJ, Campbell KF, Willis BC, Alvarado FJ, Zarzoso M, Kaur K, Perez-Hernandez M, Matamoros M, Valdivia HH, Delpon E, Jalife J (2018) Cardiac Kir2.1 and NaV15 Channels Traffic Together to the Sarcolemma to Control Excitability. Circ Res 122(11), 1501–1516. https://doi.org/10.1161/CIRCRESAHA.117.311872
Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, Napolitano C, Anumonwo J, Di Barletta MR, Gudapakkam S, Bosi G, Stramba-Badiale M, Jalife J (2005) A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96(7):800–807. https://doi.org/10.1161/01.RES.0000162101.76263.8c
Qian LL, Sun X, Yang J, Wang XL, Ackerman MJ, Wang RX, Xu X, Lee HC, Lu T (2021) Changes in ion channel expression and function associated with cardiac arrhythmogenic remodeling by Sorbs2. Biochim Biophys Acta Mol Basis Dis 1867(12):166247. https://doi.org/10.1016/j.bbadis.2021.166247
Raad N, Bittihn P, Cacheux M, Jeong D, Ilkan Z, Ceholski D, Kohlbrenner E, Zhang L, Cai CL, Kranias EG, Hajjar RJ, Stillitano F, Akar FG (2021) Arrhythmia Mechanism and Dynamics in a Humanized Mouse Model of Inherited Cardiomyopathy Caused by Phospholamban R14del Mutation. Circulation 144(6):441–454. https://doi.org/10.1161/CIRCULATIONAHA.119.043502
Reilly L, Eckhardt LL (2021) Cardiac potassium inward rectifier Kir2: Review of structure, regulation, pharmacology, and arrhythmogenesis. Heart Rhythm 18(8):1423–1434. https://doi.org/10.1016/j.hrthm.2021.04.008
Roman-Campos D, Campos AC, Gioda CR, Campos PP, Medeiros MA, Cruz JS (2009) Cardiac structural changes and electrical remodeling in a thiamine-deficiency model in rats. Life Sci 84(23–24):817–824. https://doi.org/10.1016/j.lfs.2009.03.011
Ruddiman CA, Peckham R, Luse MA, Chen YL, Kuppusamy M, Corliss BA, Hall PJ, Lin CJ, Peirce SM, Sonkusare SK, Mecham RP, Wagenseil JE, Isakson BE (2023) Polarized localization of phosphatidylserine in the endothelium regulates Kir2.1. JCI Insight 8(9). https://doi.org/10.1172/jci.insight.165715
Rudic B, Schimpf R, Borggrefe M (2014) Short QT Syndrome - Review of Diagnosis and Treatment. Arrhythm Electrophysiol Rev 3(2), 76-79. https://doi.org/10.15420/aer.2014.3.2.76
Sales NM, Pelegrini PB, Goersch MC (2014) Nutrigenomics: definitions and advances of this new science. J Nutr Metab 2014:202759. https://doi.org/10.1155/2014/202759
Sanson C, Schombert B, Filoche-Romme B, Partiseti M, Bohme GA (2019) Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying K(ir)2.1 Channels on an Automated Patch-Clamp Platform. Assay Drug Dev Technol 17(3):89–99. https://doi.org/10.1089/adt.2018.882
Sansone V, Tawil R (2007) Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 4(2):233–237. https://doi.org/10.1016/j.nurt.2007.01.005
Scherer D, Schworm B, Seyler C, Xynogalos P, Scholz EP, Thomas D, Katus HA, Zitron E (2017) Inhibition of inwardly rectifying Kir2.x channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP(2) interference. Naunyn Schmiedebergs Arch Pharmacol 390(7):701–710. https://doi.org/10.1007/s00210-017-1372-5
Van Der Schoor L, Van Hattum EJ, De Wilde SM, Harlianto NI, Van Weert AJ, Bloothooft M, Van Der Heyden MAG (2020) Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease. Int J Mol Sci 21(16). https://doi.org/10.3390/ijms21165746
Shimaoka T, Wang Y, Morishima M, Miyamoto S, Ono K (2020) Magnesium Deficiency Causes Transcriptional Downregulation of Kir2.1 and Kv4.2 Channels in Cardiomyocytes Resulting in QT Interval Prolongation. Circ J 84(8):1244–1253. https://doi.org/10.1253/circj.CJ-20-0310
Shin JJH, Gillingham AK, Begum F, Chadwick J, Munro S (2017) TBC1D23 is a bridging factor for endosomal vesicle capture by golgins at the trans-Golgi. Nat Cell Biol 19(12):1424–1432. https://doi.org/10.1038/ncb3627
Šinkovec M, Pernat A, Jan M, Antolič B, Kovač J, Podkrajšek KT, Debeljak2 M (2013) Novel KCNJ2 mutation associated with Andersen-Tawil syndrome. Zdravstveni Vestnik 82;55-60
Smith WL, Alphin RS, Jackson CB, Sancilio LF (1989) The antiemetic profile of zacopride. J Pharm Pharmacol 41(2):101–105. https://doi.org/10.1111/j.2042-7158.1989.tb06402.x
Smith DE, Hills DA, Harman C, Hawkins DA, Gazzard BG (1991) Nebulized pentamidine for the prevention of Pneumocystis carinii pneumonia in AIDS patients: experience of 173 patients and a review of the literature. Q J Med 80(291), 619–629. https://www.ncbi.nlm.nih.gov/pubmed/1946942
Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC (2018) Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve 57(4):522–530. https://doi.org/10.1002/mus.26009
Steele DF, Eldstrom J, Fedida D (2007) Mechanisms of cardiac potassium channel trafficking. J Physiol 582(Pt 1):17–26. https://doi.org/10.1113/jphysiol.2007.130245
Stockklausner C, Klocker N (2003) Surface expression of inward rectifier potassium channels is controlled by selective Golgi export. J Biol Chem 278(19):17000–17005. https://doi.org/10.1074/jbc.M212243200
Stockklausner C, Ludwig J, Ruppersberg JP, Klocker N (2001) A sequence motif responsible for ER export and surface expression of Kir2.0 inward rectifier K(+) channels. FEBS Lett 493(2–3):129–133. https://doi.org/10.1016/s0014-5793(01)02286-4
Szatmari V, Ji Y, Herwijnen BV, Feng M, Wang MZ, Bossu A, Van Der Heyden MAG (2018) Efficacy of pentamidine analogue 6 in dogs with chronic atrial fibrillation. J Vet Intern Med 32(5):1549–1554. https://doi.org/10.1111/jvim.15242
Szendrey M, Guo J, Li W, Yang T, Zhang S (2021) COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. J Pharmacol Exp Ther 377(2):265–272. https://doi.org/10.1124/jpet.120.000484
Takanari H, Nalos L, Stary-Weinzinger A, De Git KC, Varkevisser R, Linder T, Houtman MJ, Peschar M, De Boer TP, Tidwell RR, Rook MB, Vos MA, Van Der Heyden MAG (2013) Efficient and specific cardiac IK(1) inhibition by a new pentamidine analogue. Cardiovasc Res 99(1):203–214. https://doi.org/10.1093/cvr/cvt103
Tan BH, Dovat S, Peterson BZ, Song CH (2013) Reduced PIP2 Binding to KCNJ2 (M307I) Channels is Linked to Type 1 Andersen-Tawil Syndrome. Biophys J 104(2):129a–129a. https://doi.org/10.1016/j.bpj.2012.11.742
Taneja TK, Ma D, Kim BY, Welling PA (2018) Golgin-97 Targets Ectopically Expressed Inward Rectifying Potassium Channel, Kir2.1, to the trans-Golgi Network in COS-7 Cells. Front Physiol 9:1070. https://doi.org/10.3389/fphys.2018.01070
Ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ (1995) Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 73(5), 631–642. https://www.ncbi.nlm.nih.gov/pubmed/8846489
Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC, Ackerman MJ (2006) Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 3(7):800–805. https://doi.org/10.1016/j.hrthm.2006.03.025
Thienpont D, Brugmans J, Abadi K, Tanamal S (1969) Tetramisole in the treatment of nematode infections in man. Am J Trop Med Hyg 18(4):520–525. https://doi.org/10.4269/ajtmh.1969.18.520
Thomas M, Hughes TE (2020) Optically activated, customizable, excitable cells. PLoS ONE 15(12):e0229051. https://doi.org/10.1371/journal.pone.0229051
Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, Bendahhou S, Kwiecinski H, Fidzianska A, Plaster N, Fu YH, Ptacek LJ, Tawil R (2002) Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110(3):381–388. https://doi.org/10.1172/JCI15183
Trum M, Islam MMT, Lebek S, Baier M, Hegner P, Eaton P, Maier LS, Wagner S (2020) Inhibition of cardiac potassium currents by oxidation-activated protein kinase A contributes to early afterdepolarizations in the heart. Am J Physiol Heart Circ Physiol 319(6):H1347–H1357. https://doi.org/10.1152/ajpheart.00182.2020
Turco L, Reiberger T, Vitale G, La Mura V (2023) Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int 43(6):1183–1194. https://doi.org/10.1111/liv.15559
Utrilla RG, Nieto-Marin P, Alfayate S, Tinaquero D, Matamoros M, Perez-Hernandez M, Sacristan S, Ondo L, De Andres R, Diez-Guerra FJ, Tamargo J, Delpon E, Caballero R (2017) Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated than Kir2.1 and Nav1.5 Channels Alone. Front Physiol 8:903. https://doi.org/10.3389/fphys.2017.00903
Van Ert HA, Mccune EC, Orland KM, Maginot KR, Von Bergen NH, January CT, Eckhardt LL (2017) Flecainide treats a novel KCNJ2 mutation associated with Andersen-Tawil syndrome. HeartRhythm Case Rep 3(2):151–154. https://doi.org/10.1016/j.hrcr.2016.11.009
Varghese A (2016) Reciprocal Modulation of IK1-INa Extends Excitability in Cardiac Ventricular Cells. Front Physiol 7:542. https://doi.org/10.3389/fphys.2016.00542
Varkevisser R, Houtman MJ, Waasdorp M, Man JC, Heukers R, Takanari H, Tieland RG, Van Bergen En Henegouwen PM, Vos MA, Van Der Heyden MAG (2013). Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine. Pflugers Arch 465(2); 247-259. https://doi.org/10.1007/s00424-012-1189-5
Veerapandiyan A, Statland JM, Tawil R (2018) Andersen-Tawil Syndrome.Gene Reviews, Seattle
Veeraraghavan R, Gourdie RG, Poelzing S (2014) Mechanisms of cardiac conduction: a history of revisions. Am J Physiol Heart Circ Physiol 306(5):H619-627. https://doi.org/10.1152/ajpheart.00760.2013
Villar-Quiles RN, Sternberg D, Tredez G, Beatriz Romero N, Evangelista T, Laforet P, Cintas P, Sole G, Sacconi S, Bendahhou S, Franques J, Cances C, Noury JB, Delmont E, Blondy P, Perrin L, Hezode M, Fournier E, Fontaine B, Stojkovic T, Vicart S (2022) Phenotypical variability and atypical presentations in a French cohort of Andersen-Tawil syndrome. Eur J Neurol 29(8):2398–2411. https://doi.org/10.1111/ene.15369
Vivekanandam V, Mannikko R, Skorupinska I, Germain L, Gray B, Wedderburn S, Kozyra D, Sud R, James N, Holmes S, Savvatis K, Fialho D, Merve A, Pattni J, Farrugia M, Behr ER, Marini-Bettolo C, Hanna MG, Matthews E (2022) Andersen-Tawil syndrome: deep phenotyping reveals significant cardiac and neuromuscular morbidity. Brain 145(6):2108–2120. https://doi.org/10.1093/brain/awab445
Wagner S, Hacker E, Grandi E, Weber SL, Dybkova N, Sossalla S, Sowa T, Fabritz L, Kirchhof P, Bers DM, Maier LS (2009) Ca/calmodulin kinase II differentially modulates potassium currents. Circ Arrhythm Electrophysiol 2(3):285–294. https://doi.org/10.1161/CIRCEP.108.842799
Wagner M, Riepe KG, Eberhardt E, Volk T (2010) Open channel block of the fast transient outward K+ current by primaquine and chloroquine in rat left ventricular cardiomyocytes. Eur J Pharmacol 647(1–3):13–20. https://doi.org/10.1016/j.ejphar.2010.08.007
Walsh R, Adler A, Amin AS, Abiusi E, Care M, Bikker H, Amenta S, Feilotter H, Nannenberg EA, Mazzarotto F, Trevisan V, Garcia J, Hershberger RE, Perez MV, Sturm AC, Ware JS, Zareba W, Novelli V, Wilde A, a. M., Gollob, M. H. (2022) Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J 43(15):1500–1510. https://doi.org/10.1093/eurheartj/ehab687
Wang HR, Wu M, Yu H, Long S, Stevens A, Engers DW, Sackin H, Daniels JS, Dawson ES, Hopkins CR, Lindsley CW, Li M, Mcmanus OB (2011) Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem Biol 6(8):845–856. https://doi.org/10.1021/cb200146a
Weaver CD, Denton JS (2021) Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology. Am J Physiol Cell Physiol 320(6):C1125–C1140. https://doi.org/10.1152/ajpcell.00548.2020
Welland NL, Haestad H, Fossmo HL, Giltvedt K, Orstavik K, Nordstrom M (2021) The Role of Nutrition and Physical Activity as Trigger Factors of Paralytic Attacks in Primary Periodic Paralysis. J Neuromuscul Dis 8(4):457–468. https://doi.org/10.3233/JND-200604
Wibowo E, Pollock PA, Hollis N, Wassersug RJ (2016) Tamoxifen in men: a review of adverse events. Andrology 4(5):776–788. https://doi.org/10.1111/andr.12197
Wijesurendra RS, Casadei B (2019) Mechanisms of atrial fibrillation. Heart 105(24):1860–1867. https://doi.org/10.1136/heartjnl-2018-314267
Wu L, Wang Q, Gu J, Zhang H, Gu Y (2020) Modulation of Actin Filament Dynamics by Inward Rectifying of Potassium Channel Kir2.1. Int J Mol Sci 21(20). https://doi.org/10.3390/ijms21207479
Xia M, Jin Q, Bendahhou S, He Y, Larroque MM, Chen Y, Zhou Q, Yang Y, Liu Y, Liu B, Zhu Q, Zhou Y, Lin J, Liang B, Li L, Dong X, Pan Z, Wang R, Wan H, Qiu W, Xu W, Eurlings P, Barhanin J, Chen Y (2005) A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 332(4):1012–1019. https://doi.org/10.1016/j.bbrc.2005.05.054
Xie LH, John SA, Ribalet B, Weiss JN (2008) Phosphatidylinositol-4,5-bisphosphate (PIP2) regulation of strong inward rectifier Kir2.1 channels: multilevel positive cooperativity. J Physiol 586(7):1833–1848. https://doi.org/10.1113/jphysiol.2007.147868
Yim J, Kim KB, Kim M, Lee GD, Kim M (2021) Andersen-Tawil Syndrome With Novel Mutation in KCNJ2: Case Report. Front Pediatr 9:790075. https://doi.org/10.3389/fped.2021.790075
Yuan Z, Hansen SB (2023) Cholesterol Regulation of Membrane Proteins Revealed by Two-Color Super-Resolution Imaging. Membranes (Basel) 13(2). https://doi.org/10.3390/membranes13020250
Zaklyazminskaya E, Polyak M, Shestak A, Sadekova M, Komoliatova V, Kiseleva I, Makarov L, Podolyak D, Glukhov G, Zhang H, Abramochkin D, Sokolova OS (2022) Variable Clinical Appearance of the Kir2.1 Rare Variants in Russian Patients with Long QT Syndrome. Genes (Basel) 13(4). https://doi.org/10.3390/genes13040559
Zaks-Makhina E, Li H, Grishin A, Salvador-Recatala V, Levitan ES (2009) Specific and slow inhibition of the kir2.1 K+ channel by gambogic acid. J Biol Chem 284(23):15432–15438. https://doi.org/10.1074/jbc.M901586200
Zangerl-Plessl EM, Qile M, Bloothooft M, Stary-Weinzinger A, Van Der Heyden MAG (2019) Disease Associated Mutations in K(IR) Proteins Linked to Aberrant Inward Rectifier Channel Trafficking. Biomolecules 9(11). https://doi.org/10.3390/biom9110650
Zaza A, Rocchetti M, Brioschi A, Cantadori A, Ferroni A (1998) Dynamic Ca2+-induced inward rectification of K+ current during the ventricular action potential. Circ Res 82(9):947–956. https://doi.org/10.1161/01.res.82.9.947
Zhai XW, Zhang L, Guo YF, Yang Y, Wang DM, Zhang Y, Li P, Niu YF, Feng QL, Wu BW, Cao JM, Liu QH (2017) The IK1/Kir2.1 channel agonist zacopride prevents and cures acute ischemic arrhythmias in the rat. PLoS One 12(5):e0177600. https://doi.org/10.1371/journal.pone.0177600
Zhang H, Garratt CJ, Zhu J, Holden AV (2005a) Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans. Cardiovasc Res 66(3):493–502. https://doi.org/10.1016/j.cardiores.2005.01.020
Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, George AL, Horie M, Andelfinger G, Snow GL, Fu YH, Ackerman MJ, Vincent GM (2005b) Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 111(21):2720–2726. https://doi.org/10.1161/CIRCULATIONAHA.104.472498
Zhang L, Liu Q, Liu C, Zhai X, Feng Q, Xu R, Cui X, Zhao Z, Cao J, Wu B (2013a) Zacopride selectively activates the Kir2.1 channel via a PKA signaling pathway in rat cardiomyocytes. Sci China Life Sci 56(9):788–796. https://doi.org/10.1007/s11427-013-4531-z
Zhang Y, Sun L, Zhang Y, Liang H, Li X, Cai R, Wang L, Du W, Zhang R, Li J, Wang Z, Ma N, Wang X, Du Z, Yang B, Gao X, Shan H (2013b) Overexpression of microRNA-1 causes atrioventricular block in rodents. Int J Biol Sci 9(5):455–462. https://doi.org/10.7150/ijbs.4630
Zhang P, Xu J, Hu W, Yu D, Bai X (2018) Effects of Pinocembrin Pretreatment on Connexin 43 (Cx43) Protein Expression After Rat Myocardial Ischemia-Reperfusion and Cardiac Arrhythmia. Med Sci Monit 24;5008–5014. https://doi.org/10.12659/MSM.909162
Zobel C, Cho HC, Nguyen TT, Pekhletski R, Diaz RJ, Wilson GJ, Backx PH (2003) Molecular dissection of the inward rectifier potassium current (IK1) in rabbit cardiomyocytes: evidence for heteromeric co-assembly of Kir2.1 and Kir2.2. J Physiol 550(Pt 2):365–372. https://doi.org/10.1113/jphysiol.2002.036400
Funding
E. Li has received research support from the China Scholarship Council.
Author information
Authors and Affiliations
Contributions
All authors contributed to the review’s conception and design. E. Li drafted and MvdH critically revised the work. All authors read and approved the final manuscript. The authors confirm that no paper mill and artificial intelligence was used.
Corresponding author
Ethics declarations
Ethics approval and consent to participate and publish
Not relevant.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Li, E., van der Heyden, M.A.G. The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues. Naunyn-Schmiedeberg's Arch Pharmacol (2024). https://doi.org/10.1007/s00210-024-03116-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00210-024-03116-5